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1.1 Allogeneic Bone Marrow Cell Transplantation 
 
Over the past years there has been significant improvement in conventional therapies 
for cancer, but still mortality due to this disease remains high and thus calls for a 
need of a combination of conventional and biological therapeutic approaches. 
Several approaches such as blockade of neoangiogenesis, modulation of matrix 
degrading enzymes, cancer gene therapy and immunotherapy procedures aiming at 
targeting tumor antigens are in practice [1-3]. It is only recently that we have gained 
better and deeper insight towards the molecular basis of immunology approach and 
still a lot has to be done to use immunotherapy alongside with surgery, 
chemotherapy, and radiotherapy as an equally efficient and at the same time a less 
harmful therapeutic strategy [4]. 
 
Allogeneic bone marrow transplantation (BMT) is one of the tools for immunotherapy 
of cancer. It involves transfer of bone marrow or hematopoietic stem cells from donor 
to host with matched histocompatibility [5]. Allogeneity is defined by a multigene 
system known as major histocompatibility complex (MHC). The gene products are 
called HLA in humans and H-2 in mice. HLA complex in humans is located on the 6th 
chromosome. H-2 complex in mice is located on the 17th chromosome [6]. These 
molecules are central in T cell activation. HLA and H-2 class I molecules present 
peptides to CD8+ T cells whereas, class II present peptides to CD4+ T cells [7, 8]. 
During the process of maturation of the immune system tolerance develops against 
these peptides such that, self peptides are tolerated by the immune system. 
Rejection of transplanted tissues and organs within a species is caused by 
recognition of proteins encoded by MHC genes according to the allelic polymorphism. 
Differences in the MHC Ags between a transplant donor and recipient lead to rapid 
elimination of the graft; however, polymorphisms in other genes can also cause 
rejection of tissues in MHC-matched individuals. These minor histocompatibility Ags 
(mHAgs)  are  presented  as  peptide fragments derived from proteins with more than  
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one allele that are presented by class I MHC molecules, initiating a CD8+ CTL 
response [9]. The outcome of this is the probability of graft vs host disease (GVHD), 
graft rejection as well as differentiation between graft vs host disease and  graft vs 
tumor activity [5].  
 
Earlier it was believed that bone marrow cell transplantation (BMCT) could only be 
employed for hematological malignancies to replace patient’s hematopoiesis after 
chemotherapy or radiotherapy [10]. Allogeneic BMT indeed provides a cell graft that 
is tumor free, as well as cells that have not been damaged by prior chemotherapy or 
radiotherapy and most importantly stem cells that can differentiate and constitute a 
functional hematopoietic system in the patient. However, until recently allogeneic 
bone marrow transplantation could be given only to younger patients due to 
myeloablative conditioning where the host relies completely on the donor bone 
marrow cells for total hematopoietic reconstitution. There is high toxicity involved in 
this process because myeloablation requires high doses of chemotherapeutic drugs 
and /or radiation dose [11, 12]. Thus, older patients develop high rate non relapse 
mortality probably due to poor engraftment and high susceptibility to infections as a 
consequence of particularly impaired reconstitution of immune cells form the 
allogeneic graft. The poor recovery of functionally active immune cells is atleast, 
partly due to thymus involution with age where the thymus is essentially required for 
T cell maturation. Since the median age of people with hematological malignances is 
>50, there was a need to develop a protocol that would suit the elderly. Recent 
evidence in animal models and first clinical trials suggests that non-myeloablative 
conditioning before allogeneic bone marrow transplantation (BMCT) could be 
tolerated by elderly patients as well as those in poor health [11, 12]. The non- 
myeloablative or myeloreductive conditioning is less toxic to patients and hence has 
a better outcome because it is less intensive and involves lower doses of 
chemotherapeutic drugs or radiation dose. These regimens typically use 
combinations of chemotherapy drugs such as fludarabine, busulfan, ATG and 
melphalan, with or without low-dose radiation. It became evident that this approach 
has an efficient therapeutic effect of inducing an immune response for the tumor that  
 
INTRODUCTION 
                                                                    
                    
                                                                      6 
 
is allogeneic for the grafted cells. However there are also some problems connected 
to it such as how to reduce graft versus host disease without affecting anti-tumor 
activity, T cell dysfunction and delayed immune response [13]. In theory allogeneic 
bone marrow transplantation could serve as  an ultimate curative therapy for patients 
with hematological malignancies as well as solid tumors which has been reported for 
renal cell carcinoma [14].  
 
1.1.1 Graft versus host disease (GVHD) after allogeneic BMCT 
 
The danger of GVHD development is an important consideration in allogeneic BMCT 
and is irrespective of the conditioning regimen i.e. myeloablative or non- 
myeloablative. It is a condition in which immune cells or precursors of immune cells 
of the immunocompetent donor develop a strong immune response against the 
immunodeficient host. The host being immunodeficient allows the engraftment of the 
donor. Clinical GVHD has an acute and a chronic form. The acute form develops 
within 100 days and is characterized by damage to skin, liver and gastrointestinal 
tract. The chronic form of GVHD develops after 100 days and with problems like 
autoimmune syndromes such as eosinophilic fasciitis [15].  
 
So, we need to design tools that can inhibit GVHD but at the same time retain graft 
versus tumor (GVT) activity. Several approaches are being proposed and studied but 
till date no approach has proved to be ideal in solving the problem completely. 
Patients receive immune suppressive drugs so that the T cells accompanying the 
graft do not react with host cells. However, immune suppressive drugs impair 
immune reconstitution of the host to a large extent. Another approach is to deplete T 
cells from the graft [16]. αβ T cells are one of the main inducers of GVHD. Both CD4 
and CD8 T cells can induce GVHD corresponding to MHC mismatch. In all minor 
HLA mismatched models CD8 T cells are most likely involved in mediating GVHD. 
But, CD4 T cells can also help inducing GVHD and in addition they support CD8 T 
cell mediated effects [15].  
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Blockade of co-stimulatory molecules would be an ideal tool since T cells require 
signals from co-stimulatory cells for their activation and function. Many concepts deal  
with blocking T cell activation directly or through co-stimulatory molecules such as 
application of anti-TCR, anti-CD40L or anti-CTLA-4Ig resulting in significant decrease 
in GVHD.  Depletion of CD4 T cells which are thought to favor GVHD and addition of 
small number of CD8 T cells could favor engraftment [17-20]. Infusion of regulatory T 
cells (Tregs) is also being widely accepted.  Tregs are a group of T cells that suppress 
the function of other immune cells, thus regulating homeostasis, tolerance and 
preventing over response against antigens. It has been shown that Tregs are involved 
in controlling GVHD and can also differentiate between GVHD and GVT. This feature 
of Tregs could be manipulated during BMC transplantation such that they can 
suppress GVHD and retain GVT reactivity [21]. The exact mechanisms by which Tregs 
mediate these effects are not fully understood. Some studies speculate that they 
suppress expansion of alloreactive donor T cells as well as the IL-2 receptor α-chain 
and do not interfere with GVT reactivity that is primarily mediated via perforin lysis 
pathway mediated by CD8 cytotoxic T cells [22].  
 
Scheme A.  Model of Graft vs Host disease   adopted from[15] 
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1.1.2 Tumor vaccination after allogeneic bone marrow transplantation   
 
Tumor antigens are molecules on a tumor cell that can be recognized by immune 
cells. They are either tumor specific (expressed only on tumor cells and not in normal 
cells) or tumor associated antigens (expressed at lower levels in normal cells) [23].  
We know that patients bearing tumors don’t mount an efficient immune response. So 
there is a need for an external stimulus to trigger anti-tumor response. For this 
purpose vaccination could be a useful tool to boost the immune system.  
 
Allogeneic BMT along with vaccination including whole tumor cell vaccine from the 
recipient produces a good graft vs tumor (GVT) response but it comes along with 
high GVHD.  High GVHD is due to minor histocompatibility antigens on the whole 
tumor cell vaccine. Donor T cells immunized against a specific tumor antigen and not 
against minor histocompatibility antigens (mHAgs) would be efficient in attacking the 
tumor without GVHD. For this purpose vaccines directed against a tumor specific 
antigen and delivered in the form of DNA or RNA coding for tumor antigens or 
proteins have evolved that would not immunize T cells against mHAgs and thus only 
mediate GVT efficiently without causing GVHD [24]. One such example is the murine 
ubiquitin gene fused to murine melanoma peptide epitopes gp100 (25-35) and TRP-2 
(181-188) when administered (oral DNA vaccine), leads to rejection of a murine 
melanoma line. Immunity against the tumor was mediated by MHC class I restricted 
CD8 cells along with the help of CD4 T cells. The anti-tumor mechanisms involved 
high secretion of TNF-α and IFN-γ, increased expression of co-stimulatory molecules 
CD28 on T cells and B7.1 and CD48 on antigen presenting cells (APCs)  Ex vivo 
primed dendritic cells have emerged as a good source for antigen presentation and 
triggering T cell activation [25-27]. 
  
When vaccination is given against a tumor antigen the cytotoxic T lymphocytes 
(CTLs) become activated and kill the tumor cells. However, for a sufficient immune 
response T helper cells also have to be activated since they release cytokines that 
are necessary for activating CTLs [28]. A major drawback associated with tumor 
vaccination is inefficiency of the immune system to respond actively. Vaccination can  
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fail when the immune system becomes tolerant towards the tumor antigens or 
effector cells induced in due course of vaccination can attack tumor as well 
differentiating cells on the system leading to autoimmune response and GVHD [29, 
30].  
However, before considering vaccination protocols in allogeneically reconstituted 
host, the question on how to re-establish a competent immune system needs to be 
solved. Because intra thymic maturation of T cells is a prerequisite to reach this goal, 
we have to come back to the chapter on the inherent difficulties accompanied by 
allogeneic hematopoietic stem cell transplantation, which includes the problem of 
thymus involution with age.  
 
1.1.3 Thymus involution 
 
Thymus is the central organ for T cell development and in adults there is a 
confrontation of the problem of thymus involution which is of grave concern in 
allogeneic bone marrow transplantation setup [31]. Involution of thymus (thymic 
atrophy) starts at a young age, epithelial space starts to shrink by year one in 
humans and by middle age post parenchymal tissue is replaced by fat; nevertheless 
thymus is functional till the age of 60 although maturation of T cells and emigration 
into periphery is about 5% of that in younger individuals [31-33]. In the normal 
scenario thymic atrophy does not affect people since the peripheral T cell pool still 
has a high capacity to proliferate and contains many memory T cells [34]. 
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Scheme B.  Age related B and T cell development  adopted from [35] 
 
 
Now the question arises on how efficient is T cell maturation after allogeneic BMT. 
Allogeneic bone marrow transplantation relies on naive T cells for immune functions. 
In younger patients that receive BMT, T cells can mature in the thymus efficiently. But 
a major problem arises in adults where T cell reconstitution is hampered by thymic 
atrophy [36].  Thus, how to regenerate the thymus and promote T cell maturation in 
allogeneic BMT is a major question in the field of BMT.  
 
Many approaches have been proposed to increase to some extent thymic 
reconstitution and thymopoiesis. One approach is implanting thymic grafts, however 
they are rarely available [37].  One of the main causes of thymic involution is said to 
be increased production of sex steroids (androgen, oestrogen and progesterone) 
after puberty. Decreasing the level of these hormones through castration helps to 
regain thymic cellularity and reformation of thymic architecture to some extent [38]. In 
addition to their role in regulating metabolism, growth hormone and insulin like growth  
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factor also play a role in hematopoiesis, lymphopoiesis, T and B cell development. 
These features can also be exploited to enhance T cell repopulation [39].  
Administration of IL-7 has many stimulatory effects on T cell development such as 
increased thymopoiesis [40], increased peripheral CD4+ and CD8+ T cells [41] and 
increased numbers of cytotoxic T cells [42]. Inspite of several approaches being 
studied till date thymus regeneration still seems to be a major concern in allogeneic 
bone marrow cell reconstitution. 
 
1.2 Thymocyte maturation 
 
Thymus is a primary lymphoid organ that essentially is required for maturation of self 
tolerant T lymphocytes from incoming bone marrow derived progenitors. It is found in 
all vertebrates with the exception of jawless fish. Its emergence came in parallel with 
the identification of VDJ gene rearrangements as a means for diversifying antigen 
receptors.  Thymopoesis is a complex process involving three main steps, first 
thymus as a site for incoming and outgoing thymocytes, second, nature of thymic 
progenitors that enter the thymus and third, development of thymocytes through 
different stages to become T lymphocytes ready to exit to the periphery. This process 
is mediated through several signaling mechanisms and interactions involving 
thymocytes and stromal environment including epithelial cells, dendritic cells, and 
fibroblasts [43].  
 
Thymocytes undergo a defined differentiation process that is characterized by the 
expression of CD4 and CD8. Double negative (DN) thymocytes, are the earliest in 
the differentiation process at which T cell progenitors lack CD4 and CD8 expression. 
They are further subdivided into DN1 through DN4 depending on the expression of 
CD44 and CD25 as follows, DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-
CD25+) and DN4 (CD44-CD25-). The next step is double positive (DP) stage 
(CD4+CD8+) and finally the single positive (SP) stage (CD4+ or CD8+). Double 
negative thymocytes compose 5% of the whole population, double positive 
thymocytes   compose   80%   and   single   positive   thymocytes   compose   10%,  
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respectively [44, 45]. DN1 cells move very slow and remain near the site of thymic 
entry (cortico medullary junction) for 9-11 days after entry. This is the time when they  
proliferate and undergo lineage commitment losing their capacity to differentiate into 
B and natural killer (NK) cells. Cells now move out of the cortico medullary junction to 
the middle cortex where they can still give rise to T or dendritic cells (DN2 stage). 
They remain there for 2 days after which they move to the outer cortex where they 
transform into DN3 cells. In approximately 13 days the transition to DP stage occurs 
in the capsule. After which they start moving towards the medulla, undergoing 
positive and negative selection and get committed towards CD4 and CD8 T cells and 




Scheme C.  Stages in thymocyte development and involvement of thymic 
environment adopted from [49] 
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1.2.1 Thymocyte homing and migration 
 
Thymocyte migration can be subdivided as follows, entry of bone marrow derived 
progenitors into thymus, migration of thymocytes from the cortex through the 
medulla, and exit to periphery [45]. 
 
1.2.1.1 Thymic progenitors 
Hematopoetic stem cells reside in the fetal liver or adult bone marrow. They have self 
renewing capacity and are able to generate cells of all blood lineages. They are the 
source of precursors such as common lymphoid (CLP) or common myeloid 
progenitors (CMP). The most primitive progenitors in the thymus are DN1 and they 
are CD4low and ckit+. More detailed analysis of this population has revealed early T 
lineage progenitor (ETP) population that is lin-ckit+CD25-IL-7Rαlow. These cells have 
T cell potential but limited B and myeloid cell potential [50].  Another study has shown 
two subsets of DN1 a and b using subfractionation of DN1 cells depending on c-kit+, 
HSAlow/- and c-kit+/HSA+, resulting in precursor progeny relationship ETP being 
precursor and DN being progeny.  ETPs were defined as a pool of DN1 a and b. 
ETPs can further be subdivided depending on expression of fms like tyrosine kinase 
3. ETPs expressing Flt3 form an immature subset and loss of Flt3 leads to loss of B 
cell potential. ETPs are said to be similar to bone marrow LSK (lin-Sca-1+cKit+) cells 
that are composed of a heterogenous population of hematopoetic cells with long and 
short term self renewal capacity. Recent LSK cells with T cell potential have been 
identified. The phenotypic similarity between ETPs and LSKs and also the presence 
of LSKs in circulating blood has led to the suggestion that a subfraction of LSK home 
into the thymus as progenitors further giving rise to thymocytes and T cells [51]. 
Another study has identified two subpopulations of bone marrow cells known as 
CLP1 (lin-c-kit+IL-7Rα+) and another population designated as CLP2 (lin-c-kitlow 
B220+) that originates from CLP1 cells in vitro. CLP2 population efficiently homes into 
thymus upon intravenous transfer and gives rise to T cells indicating that they are 
lineage committed [52].  
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Chemokines and extracellular matrix are involved in driving the thymocytes through 
the thymic region during development. They attract thymocytes at different stages 
into different regions of the organ. Thymocytes differentially express chemokine 
receptors at different stages of development. CXCL-12 is expressed in subcapsular 
and medullary region and attracts double negative and double positive thymocytes 
that express CXCR4. However previous data showed that CXCR4 or CXCL12 knock 
out (KO) mice still have normal thymocyte development indicating other receptors 
and chemokines that might act in parallel [45]. 
 
The chemokine CCL25 also known as TECK is expressed by thymic epithelial cells 
and dendritic cells. Its receptor CCR9 is expressed in all subsets of thymocytes with 
maximum expression on double positive thymocytes [54]. Since CCR9 is down 
regulated in mature thymocytes and the fact that there is lack of responsiveness to 
CCL25 before exit to the periphery, it is speculated that CCR9/CCL25 interactions 
might be necessary for retention of thymocytes in the thymus [45]. Lack of CCR9 
reduces but does not abolish homing and migration completely and this indicates an 
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involvement of other factors responsible for attracting as well as guiding the homing 
and migration of thymocytes such as CCL21 [43, 55]. 
 
CCL19/CCR7 mediate thymocyte exit. Higher number of thymocytes accumulate in 
the thymus in CCL19/CCR7 knockout (KO) mice leading to lesser T cells in the 






Scheme E. Chemokines and growth factors involved in thymocyte development 
adopted from [57] 
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1.2.1.3 Adhesion molecules 
 
Thymic microenvironment expresses many adhesion molecules that have also been 
proposed to be involved in thymus homing and migration. Thymocyte adhesion to the 
matrix is blocked when antibodies against fibronectin receptor (α5β1 integrin) and 
laminin receoptor (α6β1 integrin) are added. Adhesion of immature thymocytes (DN) 
is impaired when anti-VLA-4 (α4β1 integrin) and/or antagonists of α4β1 are added. In 
addition it has been suggested that moderate interactions of thymocytes with 
fibronectin are responsible for thymocyte migration. Thymocyte exit to the periphery 
is also mediated by α4β1 mediated ECM interactions [45, 58]. 
 
CD44 is very highly expressed on early thymocytes as well as on progenitors and 
plays a role in binding to the extracellular matrix. It was shown that adding antibodies 
against the adhesion molecules of CD44, α4β1 integrin and lymphocyte function 
associated antigen-1 in thymic organ cultures where T cell development was induced 
from BM progenitors inhibited the T cell development to a large extent. However 
these antibodies did not inhibit the development when fetal thymic cells were used. 
Hence this shows a prerequisite for adhesion molecules especially in the early stages 
on T cell development [59]. 
 
P-selectin and P-selectin ligand (PSGL) have been proposed to be involved in the 
recruitment of progenitors into thymus. P-selectin is expressed on thymic vessels and 
PSGL is expressed on circulating thymic progenitors. Homing capacity of progenitors 
is strongly reduced in the absence of either P-selectin or PSGL. Hence P-selectin is 
the first molecule that fulfils the requirements of recruiting progenitors into thymus 
[60]. 
 
DN1 cells express integrins α4β1, α5β1, α6β1 heterodimers that potentially bind to 
VCAM-1 (vascular cell adhesion molecule), fibronectin and laminin1 respectively. 
DN2 cells express α4β1, α5β1, α6β1, α6β4 and α4β7 that potentially bind to 
fibronectin, collagen and VCAM that have been identified in the cortex. DN3 cells 
express the same integrins as DN2 cells with the exception of β7; hence they are not  
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able to interact with VCAM-1. DN4 cells express all the same α integrins as DN3. The 
expression of β integrins has not yet been investigated [46, 48, 61]. 
 
1.2.2 Signaling in T cell development 
 
Thymocyte development from double negative to single positive CD4+ or CD8+ cells 
involves many signal transduction events which can broadly be grouped into three 
main stages involving pre-T cell receptor and αβTCR receptors expression as 
follows.  
 
Scheme F.  Signaling mediating signaling events at the TCR complex adopted from 
[62] 
 
1.2.2.1 β selection checkpoint 
 
The first checkpoint termed as β selection checkpoint occurs at the DN3 stage where 
the cells undergo screening processes for successful arrangements of TCRβ genes.  
TCRβ chain is expressed in concert with the invariant preT-α chain and CD3 signal 
transduction moleclues. Saito and co-workers have proposed that specific residues in  
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the pre-T α membrane proximal sequence induce pre-TCR oligomerisation and 
confer β-selection in vivo [63]. 
 
At this step various signaling events take place inducing proliferation as well as co-
expression of the co-receptors CD4 and CD8. Various signaling molecules have 
been proposed to be involved at this step. Small GTPases such as Ras, Rap1A, 
RhoA, Rac and cdc42 promote survival and proliferation of DN cells but not allelic 
exclusion [64]. pLCK (Y505A) and PKC (Protein Kinase C) transgene mutants 
suggest the role of PKC and Lck in allelic exclusion and in addition cell survival and 
proliferation. A membrane targeted form of PKD is able to promote proliferation as 
well as expression of CD4 and CD8. In contrast the cytoplasmic form suppresses Vβ 
and DJβ recombination. HDAC, a transcriptional repressor has been shown as a 
target for the cytoplasmic domain of PKD and HDAC includes transcription factor 
Nur77, involved in regulating apoptosis in thymocytes as one of its targets [65]. 
 
Interaction between transcription factors Egr3, RORγt and E proteins also regulate 
transition from DN to DP stage involving rapid proliferation before the TCRα gene 
rearrangement and differentiation. In accordance with the preTCR signals Egr3 
expression induces proliferation with down regulation of RORγt by inducing the 
expression of its inhibitor Id3 and vice-versa. RORγt promotes cell cycle arrest by 
inducing CpeB4, TCRα rearrangement by inducing Rag-2 and cell survival by 
increasing Bcl-xL expression [66]. 
 
PI3K/Akt Survival pathway 
 
Thymocyte development requires integration from several signaling events through 
pre-TCR, Notch, IL-7 for a programmed lineage commitment from DN to SP stage. 
The PI3K/Akt signaling acts at this point to translate these signals towards a 
functional outcome such as survival, proliferation, differentiation and allelic exclusion 
at the β-selection check point. PIP2 (phosphatidyl inositol 3,4 bisphosphate) and  
PIP3 (phosphatidyl inositol 3,4,5- triphosphate) are the two products of PI3K that 
serve as recruiting molecules for Akt and its activating kinase PDK1 [67-69]. PI3K is  
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divided into four classes, IA, IB, II and III [70]. Mice lacking the class IB subunit p110γ 
have decreased numbers of DP followed by decrease in thymic cellularity. Mice 
lacking both p110 γ and δ show increased apoptosis, decreased proliferation at the β 
selection checkpoint and DP stages [70]. PI3K activation leads to accumulation of 
phosphatidyl inositol kinase (PDK1) at the plasma membrane and activation of Akt.  
Mice with conditional deletion of PDK1 have a block at the DN4 stage of development 
[71]. Akt1 deletion leads to decrease in thymic cellularity, but Akt2 deletion alone has 
no effect. However a double deletion of Akt 1 and 2 leads to a higher number of DN3 
thymocytes and less DPs, suggesting that these Akt isoforms may be involved in β-
selection checkpoint [72]. Cell survival through Akt pathway is supposed to be 
mediated through Bcl-xL, p-Bad and A1 anti-apoptotic proteins [73]. 
 
 
Scheme G. Signaling events mediating β selection adopted from [64] 
 
1.2.2.2 Positive versus Negative selection 
 
Many theories have been proposed over the years regarding signals transmitted 
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duration of receptor binding are most likely to influence this selection process. The 
details are discussed below. Double positive thymocytes whose TCR binds with weak 
avidity towards MHC I or II receive signals from the TCR whereby they are selected 
positively and the rest undergo apoptosis. Elimination of autoreactive SP thymocytes 
in the medulla is termed as negative selection.  
 
TCR CD3 components 
 
Antigen recognition by TCR is mediated by TCR αβ or γδ which are products derived 
from DNA recombination events. Additional molecules of the TCR complex include 
CD3γδε and ζ chain and this together forms the T-cell receptor complex that 
mediates signal transduction. The subunits of the TCR are assembled at the ER and 
then transported to the cell surface. The CD3 components are able to transduce 
signals through shared functional sequence termed immunoreceptor tyrosine based 
activation motif (ITAM) [74]. 
 
Several studies in the past suggest that mutations of either TCR or associated CD3 
components highly influence thymocytes selection. Deletion of TCRα chain 
connecting peptide domain (CPM) could inhibit positive selection without affecting 
negative selection [75]. Deletion of CD3δ component suggests a role for CD3δ in 
mediating thymic selection process from DP to SP thymocytes. [76]. CD3ζ chain 
influences both positive and negative selection. Multiple ITAMS are involved in 
modulating the TCR signals and thus influencing selection. The ζ chain functions to 
amplify the signals initiated by the TCR [62, 77]. 
 
 
TCR proximal kinases, phosphatases and adaptor molecules 
 
Induction of Lck and Fyn, Src kinases and recruitment at the TCR is one of the 
earliest events following TCR stimulation. The Src kinases once activated further 
phosphorylate ITAMS in the CD3 complex. Tyrosine phosphotylation of ITAMS 
provides  docking  sites  for  recruitment  of  syk  protein  family  kinase  ZAP-70 (ζ  
INTRODUCTION 
                                                                    
                    
                                                                      21 
 
associated protein-70). Lck and fyn phosphorylate Zap-70 [78-80]. Zap70 in turn 
phosphorylates SLP-76 (SH2 domain containing leukocyte protein) and LAT (linker 
for activation of T cells). These adapter proteins lack intrinsic kinase domains, but 
phosphorylation of these proteins facilitates interaction with other signaling molecules 
[81, 82]. LAT and SLP-76 function in concert to provide docking sites for enzymes 
such as PLCγ and VAV-95 [83]. These two are responsible for further down stream 
signaling involving small G proteins of Ras family and Rho GTPases leading to ERK 
phosphorylation. T cell activation also involves signals mediating lipid kinase 
activation such as PI3K [84]. Defects in any of the molecules mentioned can lead to 
the following consequences in thymocyte development. 
 
When the catalytically active form of Lck was over expressed positive selection was 
inhibited [85]. TCR transgenic mice that don’t express Fyn showed impaired 
maturation of selected thymocytes as well as a slight reduction in negative selection. 
Therefore both Src kinases Lck and Fyn are crucial for positive and negative 
selection [62, 86]. 
 
CD45 and Csk positively and negatively regulate Src family tyrosine kinases. CD45 is 
a transmembrane tyrosine phosphatase that is essential for positive selection. Csk is 
also an important regulator of Lck and Fyn since it inactivates them by 
phosphorylating the regulaltory C-terminal tyrosine residue. On the whole Csk 
regulates the sensitivity of thymocyte stimulation whereas, CD45 contributes to both 
positive and negative selection [87] 
 
Zap-70 and Syk belong to the Syk family of tyrosine kinases. Zap-70 deficiency leads 
to inhibition of development of CD8 T cells and also non-functional CD4 cells. In mice 
Zap-70 deficiency shows a block in both CD4 and CD8 T cells.  Syk on the contrary 
can compensate for some functions of Zap-70 but cannot substitute for the 
development of single positive T cells [88, 89]. 
 
Cbl and SLP-76 serve as adaptor molecules that lack intrinsic enzymatic activity but 
can  mediate  protein-protein  interactions  with  signaling molecules influencing T cell  
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activation. Cbl deficient mice exhibit enhanced positive selection of thymocytes 
whereas SLP-76 deficient mice show a block in thymocyte development at the DN 
stage [90, 91]. 
 
Vav is a Rho-family guanine nucleotide exchange factor that is required for efficient 
TCR signaling and thymopoiesis. Vav deficient mice show inhibition in both positive 
and negative selection of thymocytes. It was proposed that this could be due to 
inefficient TCR multimerization and internalization [92]. 
 
MAPK pathways  
 
The extracellular-regulated kinase (ERK) pathway that includes Ras, Raf-1, MEK1,2 
and ERK1,2 is activated upon TCR engagement and plays a role in pre-TCR 
signaling, positive and negative selection and lineage commitment. Transgenic mice 
over expressing Ras, Raf-1 and MEK1 can inhibit positive selection but leaves 
negative selection intact [93]. The JNK SAPK group of MAPKs consists of three 
members JNK1, 2 and 3. Targeted disruption of these individual genes did not alter T 
cell development nor CD4 and CD8 numbers. Dominant negative form of JNK1 
however led to increased resistance to anti-CD3 mediated apoptotic death of 
thymocytes [94]. 
  
P38 is another MAPK member and is also reported to play an essential role in 
mediating intrathymic signals in vivo. It has been shown that P38 pathway is critical 
for negative selection of thymocytes but not positive selection [95]. Taken together 
these studies suggest that ERK is essential for positive selection whereas JNK and 
p38 mediated negative selection leading to opposite fates in immature thymocytes. 
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Scheme H. MAP Kinase pathway adopted from [62] 
 
1.2.2.3 Lineage commitment  
 
Cell fate decisions are usually controlled by conserved receptors that interact with 
evolved ligands. Hence, the lineage fate decision of thymocytes to form CD4 or CD8 
positive cells is unusual since it is regulated by clonally expressed, somatically 
generated T-cell receptors  whose specificity cannot be defined. At the end each 
mature T cells retains only one receptor CD4 that binds to MHC-II molecule or CD8 
that binds to MHC-I molecules. Two models have been proposed to explain this fate 
one was ‘instruction’ model that depends on initial signaling events initiated on 
binding of TCR complex to MHCI or MHCII along with CD4 and CD8 coreceptor or a 
random ‘Stochastic’ model where the decision takes place depending on which MHC 
molecule is interacting with the DP thymocyte. If the MHC-II interacts first with CD4 
then the CD8 co-receptor is automatically down regulated and vice-versa. Recent 
evidence suggests that the instruction model holds true [96, 97]. 
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Scheme I. CD4/CD8 lineage commitment during thymocyte development  adopted 
from [96] 
 
Studies support both strength and kinetic signaling models to explain the fate choice 
between CD4 and CD8 T cells. CD4 and CD8 co-receptors have different abilities to 
associate with Lck and this in turn instructs fate choice when DP thymocytes bind to 
MHCI or MHCII. Studies have shown that greater Lck activity favored CD4 lineage 
fate and vice-versa [98]. 
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Erk is another likely candidate that influences fate choice between CD4 and CD8. 
Complete deletion of ERK1 and ERK2 in DP thymocytes has been shown to affect 
CD4 maturation more than CD8. RasGRP1 a nucleotide guanine exchange factor 
had a greater impact on CD4 than CD8 T cell development. This possibly indicates 
that Ras/MAPK pathway is crucial for CD4 lineage fate reviewed in [99]. 
 
1.3 CD44 Molecule 
 
Adhesion molecules are cell surface glycoproteins that have a large extracellular 
domain, a transmembrane domain and an intracellular cytoplasmic domain. These 
molecules are termed adhesion since they bind strongly to specific ligands. This 
interaction is more complex in terms of sensing the extracellular environment and 
sending signals to adjacent cells. Cell adhesion molecules are becoming increasingly 
important in relation to disease processes and as targets for use in diagnostic 
pathology [100]. 
 
CD44 glycoproteins are one of the very well characterized members of the 
hyaluronate receptor family of adhesion molecules. CD44 is a Type-I family 
transmembrane protein that mediates interaction of cells to their microenvironment.   
CD44 family of adhesion molecules bind to hyaluronic acid as the major ligand. HA is 
an extracellular polysaccharide present abundantly in extracelullar cell matrix (ECM) 
[101]. The CD44 epitope was first discovered as an antigen using a monoclonal 
antibody that was raised against human white blood cells [102]. It was then identified 
that a group of polymorphic proteins had this epitope in common (80-200KD in size).  
1.3.1 Structure 
 
CD44 is encoded by a single gene spanning a 50-60 kb region [103, 104].  It has 20 
exons from which various protein products are further generated through mRNA 
splicing. The standard form is most abundant and consists of an N-terminal signal 
sequence (exon 1), a hyaluron binding module (exon 2 and 3), a stem region (exon  
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4, 5, 16 and 17), a single transmembrane domain (exon 18) and a cytoplasmic 
domain (exon 20). Alternative exon splicing of CD44 involves variable insertions of 
combinations of exons from 6-15, also known as variants 1-10 into the stem region. 
These variant isoforms of CD44 are seen mostly in epithelial cells and upregulated 
during diseases. The CD44 isoform without the variant exons is termed as CD44s  or 
hematopoietic isoform [105]. CD44 gene is highly conserved among mammals. 
Between the human and mice genomic sequence there is 85% and 87% homology in 
the N and C-terminus respectively [104]. 
 
 
Scheme J.  Structure of CD44 Molecule adopted from [106] 
 
Hyaluron binding, amino terminal domain 
 
This site contains motifs that provide as docking sites for several components of the 
extra cellular matrix. In vitro studies have revealed that interaction of CD44 with 
hyaluronic acid (HA), collagen, laminin and fibronectin promote matrix dependent cell 
migration [102, 107]. However, there is no in vivo evidence. Apart from the hyaluron 
binding sites other sites have not been mapped precisely. A stretch of 90 amino acids 
in the amino terminal globular region form the link domain, that enables the binding of 
CD44  with  HA and also other glycosaminoglycans (GAGs) [108, 109] The affinity for  
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GAGs depends on post translational modifications of CD44 such as glycosylations. 
More than one CD44 molecule binds to HA since only HA-derived oligosaccharides 




The amino terminal globular domain of the smallest CD44 isoform (CD44 standard) is 
separated from the plasma membrane by a 46 amino acids stem structure. It 
contains proteolytic cleavage sites. It also contains the variant exon region of CD44. 
The inclusion of several combinations of variant exons depends on mitogenic signals 
including stimulation of Ras-MEK-ERK pathway that regulate splicing events [111, 
112] Some variant exon segments include motifs for post translational modifications 
but less is known about the exact structure of these variants [102]. 
 
Transmembrane and cytoplasmic domain 
  
The transmembrane and cytoplasmic domain are required for efficient ligand binding 
[113]. The transmembrane domain consists of 23 hydrophobic amino acids and a 
cysteine residue (Cys286) that seems to be involved in CD44 oligomer formation. The 
cysteine residue is also responsible for recruiting CD44 molecule into lipid rafts. 
Transmembrane region has also been proposed to be associated with proteins in 
lipid rafts. However, the recruitment into lipid rafts is cell type specific. Some 
molecules like cadherins might be responsible for displacing CD44 from lipid rafts. 
The functional significance of this association in lipid rafts is still not clearly validated 
[114]. 
 
The cytoplasmic domain is encoded by exon 19 or 20. Inclusion of one or the other of 
these exons by alternative splicing generates a tailless CD44 ending at Arg294     or a 
73 amino acid long cytoplasmic tail. The cytoplasmic tail is responsible for interacting 
with other intracellular signaling molecules and for this process Ser325 and Ser291 
residues are important [115]. .Intracellular partners of CD44 and motifs in the 
cytoplasmic domain are essential for subcellular localization for e.g. leading edge of 
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lamellipodia of migrating cells as well as accessory functions of CD44 in signal 
transduction [102].  The cytoplasmic domain is known to promote Hyaluron 
internalization and thus migration of cells [116]. 
 
Scheme K. CD44 domains adopted from [106] 
1.3.2 CD44 Functions 
 
CD44 is widely expressed in different tissue types and has structural diversity that 
enables it to interact with several signaling molecules and facilitate various functional 
outcomes such as adhesion, migration, homing, proliferation, cell survival and 
apoptosis. These functions are discussed in detail below. 
1.3.2.1 Cell adhesion and migration 
 
Cell adhesion and migration are crucial for leukocytes and tumor cells in case of 
inflammation and metastasis, respectively. CD44 primarily plays a role in maintaining  
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the three dimensional structure of organs and tissues [117]. CD44 accumulates 
during several processes such as angiogenesis, wound healing and migration of cells 
across an HA substrate. HA being one of the important components of the ECM and 
CD44 being its receptor, this suggests an obvious role for CD44 in cell migration and 
adhesion [102]. Studies in a melanoma line transfected with CD44 showed that these 
cells exhibit motility on HA coated surfaces. Accordingly, an isoform of CD44 that 
does not bind to hyaluronic acid is not able to promote migration on HA. In addition, 
antibodies blocking the HA binding site of CD44 were able to block the migration of 
these cells [113].  
 
Leukocytes and metastasizing tumor cells need to migrate and localize in special 
tissues and microenvironments for their functions and nutrition in the case of tumor 
cells  [118]. Rolling of cells is generally mediated by selectins and carbohydrate 
ligands where they promote leukocyte entry into sites of inflammation [119]. In 
addition it is also mediated by CD44 and HA interactions. These processes are 
mediated by CD44v4-v7 isoforms as well as by different glycosylation patterns of 
CD44. CD44 gets localized at the leading edge of the cell and in lamellipodia 
showing evidence for cytoskeletal anchoring of CD44 on an HA matrix. 
Metalloproteinase bound protein of type-1(MT1-MMP) is recruited into lamallipodia 
through CD44. MT1-MMP in turn cleaves CD44 and allows new CD44-HA 
interactions during which migration of cells takes place. This process is mediated 
through Ras, PI3K (phosphoinositide 3-OH kinase) and cdc42/Rac. In addition 
intracellular events such as serine proteases might also support CD44-mediated 
cellular mobility by cleavage of the molecule [120-123].  
 
Endothelial cells bind to HA through their CD44 molecules and proinflammatory 
cytokines such as tumor necrosis factor (TNF) and interleukin-1β (IL-1 β) stimulate 
CD44 thus strengthening the endothelial cell HA binding and mediating leukocyte 
extravasation.  Leukocyte immigration into sites of inflammation and delayed type 





                                                                    
                    
                                                                      30 
been proposed that IM7 (anti-CD44) binds to CD44 and reduces its expression on 
leukocytes and induces proteolytic cleavage of CD44 thus blocking migration [124]. 
Antigen presenting cells, langerhans cells and dendritic cells up regulate CD44 
variants v4, v5, v6 and v9 and these epitopes of CD44 are essential in binding to T 
cells in the lymph nodes. Antibodies against these isoforms of CD44 block the 
migration of these antigen presenting cells [125]. 
 
1.3.2.2 Interaction with the cytoskeleton 
 
Reorganisation of the cytoskeleton is important for cell migration and other 
physiological processes. Since the cytoplasmic domain of CD44 does not have actin 
binding sites, CD44 binds to the actin cytoskeleton through cytoskeleton associated 
proteins ankyrin,  ERM family of proteins (ezrin, radixin and moesin) and also merlin 
[126].  
 
Ankyrin is a group of homologous proteins that is involved in segregation of integral 
membrane proteins that have their functional domain on the plasma membrane and 
is mainly involved in linking cytoplasmic domains of integral membrane proteins to 
spectrin-actin based membrane cytoskeleton. Ankyrin has several isoforms 
generated through alternative gene splicing and different gene products coding for 
the protein. This is how the protein can bind several membrane proteins and mediate 
diverse interactions with the cytoskeleton [127]. CD44 binds to ankyrin cytoskeletal 
protein linking the plasma membrane to underlying cytoskeleton. The binding affinity 
is further enhanced through GTP binding proteins [128-130]. 
 
ERM are band 4.1 superfamily proteins acting as key linkers between 
transmembrane proteins and cytoskeleton.  The ERM proteins have a 300 amino 
acid domain at the N-terminus, α-helical central region and a C-terminal domain 
which has the F-actin binding site. ERM proteins are activated by phosphorylation 
and by binding to membrane phospholipids. It is the phoshorylated (active) form of 
ERM that binds to CD44 [126]. ERM activation is regulated via Rho GTPase family. 
Binding  of  ROK,  PKC  and  phosphatidyl  inositol  4,5  bisphosphate (PIP2) to ERM  
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proteins results in phosphorylation of these proteins [131-133]. Thr567 Ezrin, Thr564 
Radixin and Thr558 Moesin phosphorylations result in rearrangement of the 
cytoskeleton [134]. 
 
CD44 binding to cytoskeleton is further regulated by its cytoplasmic domain. In 
resting cells CD44 is phosphorylated at Ser325. The switch from Ser325 
phosphorylation to Ser291 is triggered via PKC. In addition, Ser291 phosphorylation 
is also involved in directional migration of cells. How exactly CD44 is phosphorylated 
and dephosphorylated is yet to be determined. But, CD44 binding to HA triggers 
various signaling pathways including activation of PKC. A good example is ezrin that 
associates with PKC and thus promotes phosphorylation of CD44 and regulates 
binding to the cytoskeleton [115].  
 
Merlin is a member of 4.1 protein ERM family that has 65% homology to ERM 
proteins. Its activity is also regulated through phosphorylation and dephosphorylation 
[135]. Merlin does not have an actin binding site and merlin-CD44 complex cannot 
bind to cytoskeleton [136]. The ability of ERM/melrin proteins to switch between 
phosphorylated and dephosphorylated forms along with the competition between 
ERM and merlin to bind to CD44 leads to making and breaking of CD44 interactions 
with the cytoskeleton [115]. When cells are in the growth phase phosphorylated ERM 
binds to CD44 mediating cytoskeletal interactions. During this time merlin gets 
phosphorylated by PAK2 ( p21-active kinase -2) and is now unable to bind to CD44. 
During growth arrest the opposite is seen and MAPK activation is blocked [137, 138]. 
 
1.3.2.3 Interaction with cytokines, chemokines and enzymes 
 
Apart from interacting with extracellular matrix (ECM), CD44 also interacts with 
extracellular proteins and harbors growth factors. CD44 molecules have two 
consensus sequences  in exon 5 and variant 3 exon which allow increased binding of  
interferon-γ and osteopontin, thus suppressing proliferation and inducing MHC-II 
expression [139]. CD44v3 has been shown to immobilize chemokines such as 
osteopontin, scatter factor, endothelial growth factor, MIP-I β and RANTES, reviewed 
in [106]. 
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Cytokines play an essential role in regulating hematopoiesis that is regulated by 
interaction between bone marrow microenvironment and progenitor cells. Antibodies 
against CD44 v4 and v6 stimulate the production of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-6 (IL-6) [140]. Extracellular matrix 
degrading enzymes are required during tissue remodeling, wound healing, 
angiogenesis and tumor progression. CD44 plays a role by harboring matrix 
metalloproteinases such as MMP2 and MMP9 at the cell surface. CD44 monoclonal 
antibody has been shown to upregulate the expression of MMP-2 which would have 
implications in tumor metastasis, growth and lymphocyte function. [141]  
 
CD44 binds to the chemokine, osteopontin. CD44 binding to osteopontin results in 
downregulation of the anti-inflammatory cytokine IL-10 and survival of cells by IL-3 
and GM-CSF cytokines. These two cytokines share a common beta subunit and the 
distal cytoplasmic tail participates in cell survival. Binding to osteopontin also 
activates PI3K and Akt and thus is involved in the survival pathway of IL-3 [142]. 
 
CD44v3 heparan sulphate proteoglycan and v6 bind to epidermal growth factor, 
heparin binding epidermal growth factor and fibroblast growth factor and present in 
an efficient way to their receptors for survival and proliferation of leukocytes and 
tumor cells. One example is CD44v3 heparan sulphate proteoglycan that recruits 
proteolytically active MMP-9 and heparin binding epidermal growth factor precursor 
(pro-HB-EGF) that in addition activates its receptor ErbB4 which is involved in cell 
survival [143]. CD44v3 isoform efficiently binds to hepatocyte growth factor/scatter 
factor (ligand for receptor tyrosine kinase) through its heparin sulphate chain. The 
functional outcome is promotion of c-met phosphorylation, MAPK activation and 
increased tumor growth and metastasis [144]. 
 
 
Taken together the binding of cytokines, enzymes and chemokines to CD44 is 
essential for organogenesis, hematopoesis, inflammatory and autoimmune 
responses and tumor progression. 
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1.3.2.4 CD44 as a co-receptor and signaling  
 
Many if not all signaling events are initiated through extracellular stimuli, followed by 
activation of receptor tyrosine kinases.  These receptors span the plasma membrane 
and their cytoplasmic domains have catalytic kinase activities that get phosphorylated 
upon ligand binding or other sources of stimulation and further serve as docking sites 
for several components of intracellular signaling. Receptor activation is mediated by 
several other proteins that are associated with them and which are devoid of catalytic 
activity (co-receptor activity). Cell adhesion molecules are now being known for their 
co-receptor activity [145] and CD44 is one of them. The multifunctional CD44 
molecules are known to be involved in various signaling cascades starting from 
growth and proliferation, survival, apoptosis, cytoskeletal organization, cell motility 
and adhesion. 
 
Since cytoskeletal organization and cell migration have been dealt with in the 
previous sections this section will mainly focus on cell growth proliferation, survival, 






                                                                    
                    
                                                                      34 
 
Scheme L. Signaling mediated by CD44  adopted from [101] 
 
 
One main reason for the involvement of CD44 in multiple signaling events is its 
association with the Src family of phospho tyrosine kinases (PTKs). Src kinases act 
as molecular switches on the cell membranes linking extracellular events to 
intracellular signaling.  They are activated through engagement with many receptors 
such as TCR/CD3 complex, CD4, CD8, B cell receptor, Fc receptors, integrins, GPI 
anchored receptors and growth factor receptors, reviewed in [106]. When activated 
they mediate several signaling events including activation of additional PTKs such as 
ZAP-70 or Syk, phospholipases, cytoskeletal proteins and adaptor proteins.  
 
CD44 signaling can result in opposing effects depending on the cellular context, the 
expressed variant isoform and the associated signaling partner. For example, CD44 
engagement can lead to proliferation or inhibition of proliferation, apoptosis or 
inhibition of apoptosis, resulting in upregulation and down regulation of several 
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Scheme M. Accessory functions and signaling via CD44  adopted from [146] 
 
 
CD44 associates with Lck and Lyn Src kinases in non stimulated T and B cells. It was 
shown that synthetic peptide of CD44, pCD44 (ILAVCIAVNSRRR) has high binding 
capacity towards these Src kinases. This peptide region corresponds to plasma 
membrane-cytoplasmic domain interface of CD44. A single mutation in the cysteine 
residue is enough to abolish the interaction [147]. Src kinases cotranslocate with 
CD44 by binding to CD44 carboxyl-terminal ankyrin domain which in turn facilitates 
integrin β1 recruitment and activation in lipid rafts and mediates matrix derived  cell 
survival [148]. Signaling of CD44 mediated through its association with Lck leads to 
phosphorylation of Pyk2, a focal adhesion kinase which leads to cytoskeleton 
reorganization and cell spreading [149].  
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T cell activation requires two signals one from the TCR and the other from a co-
stimulatory molecule. CD44 has been described to deliver co-stimulatory signals for T 
cell activation [150]. CD44 and the associated Lck are recruited into membrane 
microdomains (low density sucrose gradient fractions) where they interact with the 
CD3/TCR complex. Association of CD44 with Lck and Fyn and in turn their co-
localisation with the TCR allow for recruitment of several other kinases necessary for 
T cell activation [150, 151].  The co-stimulatory function of CD44 is demonstrated by 
its ability to induce cell proliferation on freshly isolated lymph node cells in the 
presence of sub threshold levels of anti-CD3. This is mediated by activation of 
several tyrosine kinases and is accompanied by strong activation of erk and c-jun 
and involvement of MAPK. Consequently, IL-2 production and CD69 and CD25 
expression are up regulated in T cells. The situation differs in the T helper line IP-12 
where it was observed that CD44-cross-linking with CD3 leads to upregulation of 
CD95 and CD95L expression resulting in apoptosis induction or activation induced 
cell death (AICD). This argues for the differential effects of CD44 on different cell 
types. In the T helper line apoptosis was mediated through CD95 and CD95L 
upregulation. It is important to note that, in both peripheral T cells and T helper line 
(IP12) CD44 cross linking alone did not exert any effect on signaling by itself [150].  
 
The effects of anti-CD44 Ab treatment are specific for the epitope of CD44 where it 
binds  i.e.  co-stimulatory  functions  of CD44 inducing  proliferation or  apoptosis  are 
exhibited only by cross-linking with IM-7 that does not bind to hyaluron binding site 
and not by KM81 binding to hyaluron binding domain of CD44 or K926 that binds to 
CD44v10 [150]. Some studies have shown that CD44 by itself is capable of activating 
human resting T cells and mouse cytotoxic T cells like CD3 and can promote 
proliferation of T cells that is dependent on IL-2 production. In this study, anti-CD44 
cross-linking does not phosphorylate the Zeta chain of the TCR complex indicating 
that the signals generated in this case are independent of TCR engagement. Indeed, 
it was demonstrated that  this process is mediated by tyrosine kinases associated 
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In a TNBS-induced colitis mouse model, CD44v7 was shown to deliver anti-apoptotic 
signals and protect T cells from activation induced cell death. Cells were protected 
from apoptosis by upregulation of anti-apoptotic proteins Bcl-2 and Bcl-xl and down 
regulation of CD95L  [153]. It was also demonstrated in this work that the anti-
apoptotic effect of CD44v7 is mediated via Akt and phosphorylation of the pro-
apoptotic molecule Bad [153].  
 
Using a mouse model for the autoimmune disease alopecia areata Marhaba et al. 
have shown an association between CD44 and CD49d. This association resulted in 
the formation of a signaling complex between CD44, CD49d and the underlying 
signaling machinery allowing for each surface molecule (CD44 or CD49d) to avail 
from the associated signaling molecules of the other. In this case, cross-linking of 
CD44 resulted in the activation of the focal adhesion kinase (FAK) associated with 
CD49d and CD49d cross-linking allowed the activation of Ezrin and Lck associated 
with CD44. Thus signaling pathways initiated through both the molecules CD44 and 
CD49d are triggered and this is important in lymphocyte activation and function [154]. 
 
CD44 signaling also mediates proliferation and apoptosis in several tumor lines 
depending on the cell type and engagement of CD44 isoform as discussed below. 
The Src-kinase Lyn, was found to be activated via CD44v6 in a colorectal cancer cell 
line. The functional relevance was, increased chemoresistence against the drug 1,3-
bis (2-chloroethyl)-1-nitrosurea and this was mediated through the PI3K/Akt survival 
pathway [155]. In an ovarian tumor, CD44 association with c-Src was responsible for 
cytoskeletal reorganization mediated by phosphorylation of the cytoskeletal protein 
cortactin leading to increased migration and spreading [156]. A thymoma line (EL4) 
transfected with CD44v6 was subjected to much higher proliferation rates as 
compared to untransfected cells that express only CD44 standard isoform. Signaling 
molecules, erk, c-jun were activated and IKappa B was phosphorylated suggesting 
NFkB activation. Indeed, NFκβ was found to be translocated to the nucleus. 
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On the other hand, CD44 was also shown to strengthen dexamethasone induced 
apoptosis of a lymphoma line that was mediated through upregulation of the pro-
apoptotic protein Bax and down regulation of the anti-apoptotic protein Bcl-Xl. The 
same effect by CD44 was also seen in thymic epithelial cells mediating apoptosis of a 
lymphoma line [158]. CD44 cross-linking in fibroblast derived  cells drives them into 
apoptosis suggesting a role for CD44 in fibroblasts [159]. CD44 ligation induced 
apoptosis of a promyelocytic leukemia line. Apoptosis was initiated via caspase 8 and 
in addition effector caspase 3. Serine protease dependent pathway was also 
proposed to be involved in mediating apoptosis of these cells [160].  
 
With respect to tumors, it has been proposed that HA-CD44 interaction mediates 
proliferation and soluble CD44 inhibits the growth of cells. When a murine mammary 
cell line was transfected with soluble CD44, it was observed that the cells no longer 
attached to the peritoneal wall and also did not form tumors. This led to inhibition of 
anchorage dependent growth as well as tumor invasion [161]. CD44-HA interaction 
also promotes neo angiogenesis and proliferation. Hyaluronic acid dependent 
clustering of CD44 promotes binding of MMP-9 to CD44 at the cell surface promoting 
its activity in addition to protecting it from tissue inhibitors for MMPs and thus 
promoting tumor invasion and angiogenesis [162]. 
 
One of the main events mediated by CD44 is cytoskeletal organization which is 
energy dependent and requires an intact actin and microtubulin system. Small 
GTPase Rac1 activation is required for this process. Rac1 is also known to co-
localise with ezrin [163]. These events along with phosphotyrosine kinase activations 
are responsible for cytoskeletal re-organizations in the cell. In T lymphocytes cross-
linking anti-CD44 leads to CD44 dependent spreading through F-actin 
polymerization, accompanied by T cell adhesion, flattening and spreading [151]. 
Vav1 protein encoded by vav protooncogene is a 95KD protein that is an upstream 
regulator of Rac1. Vav catalyses the GDP to GTP exchange on Rac1. Vav1 
activation involves phosphoinositides binding and tyrosine phosphorylation that is 
dependent on Src family kinases (Lck and Fyn) which associate with CD44. This 
could  be a  possible  explanation  for  CD44  mediated  effects  on  the  cytoskeleton  
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[151, 164, 165]. CD44 is co-localized in membrane microdomains (lipid rafts) where it 
interacts with Annexin II in a cholesterol dependent manner. The recruitment of CD44 
in rafts further leads to stabilization of actin-cytoskeleton [166]. 
 
1.3.2.5 CD44 in the context of allogeneic bone marrow transplantation 
 
CD44v7 isoform present on the bone marrow stroma supports homing of progenitors 
into the bone marrow and this was shown by injecting CD44v7+/+  BMC into the 
CD44v7-/- mice and vice versa [167]. CD44v10 isoform was proposed to play a role in 
maturation of hematopoietic cells using in vivo and in vitro blocking studies with a 
receptor globulin as well as monoclonal antibody specific for v10 isoform. It also 
plays a role in efficient mobilization of progenitors and this could be exploited for use 
in bone marrow transplantation [168]. When mice with a transgene for rat CD44v4-v7 
were used in comparison to the wild type for syngeneic and allogeneic bone marrow 
transplantation it was observed that the former had an advantage for repopulation. 
The total number of thymocytes recovered in this case was more and in this regard 
more T cells were obtained from spleen and lymph nodes. The T cells were also 
more functional compared to the non transgenic mice (NTG). Another observation 
made was that host reactive T cells were significantly reduced in the case of TG mice 
that could be due to tolerance induction [169]. Hence a more detailed investigation of 
the role of CD44 and its mechanism with regard to allogeneic bone marrow cell 
reconstitution (BMT) could prove this molecule as a convincing therapeutic target 
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Aims of study 
 
Active vaccination in the allogeneically reconstituted tumor bearing host essentially 
requires donor T cell tolerance. To create a basis for vaccination in the allogeneically 
reconstituted, lymphoma-bearing host and for improving homing of progenitors into  
thymus, A) we aimed to elaborate a reconstitution protocol where progenitor T cells 
were injected along with bone marrow cells depleted of T cells. We were interested to 
investigate the potential role of these thymocytes in homing into the thymus, anti-host 
reactivity as well as suitability for vaccination with this experimental setup. Based on 
the results of this study and in view of the fact that CD44 has been suggested to fa-
cilitate progenitor homing and settlement in the bone marrow as well as being a  T 
progenitor marker B) we explored whether CD44 standard (CD44s) and/or variant 
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Mice Type Origin 
129SVEV Wild type Charles River, 
Suzfeld, Germany 
CD44v6 intercross (CD44v7 exon KO) [170] 
CD44v6-28 (CD44v6/7 KO) [170] 
Balb/c Wild type Charles River, 
Suzfeld, 
Germany 






2.1.2 Cell Lines 
Cell Line Origin 
EL-4 
EL-4 transfected with CD44v6 
American Type Tissue Culture (ATCC) 
[157] 
IM7.8.1 mAb IM7.8.1 producing hybridoma line (ATCC) 
A2.6 mAb A2.6 (rat-CD44v6) producing hybridoma line 
(ATCC) 
145-2C11 mAb (CD3) (ATCC) 
 
2.1.3 Primers 
F   5’-GATCCATGAGTCACAGTGCG-3’ CD44s 
R  5’-GCCTACTGGAGATCAGGATG-3’ 
F   5’-CTCCTAATAGTACAGCAGAA-3’ CD44v6 
R  5’-GCCTACTGGAGATCAGGATG-3’ 
 
CD44v7 F  5’-CTTCGGCCCACAACAACCAT-3’ 
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R 5’-GCCTACTGGAGATCAGGATG-3’ 








2.1.4 Primary antibodies 
Antibody Species 
Anti-CD3 (145-2C11) ATCC 
Anti –myc ATCC 
Anti -rCD44v6 (A2.6) Matzku et al. 1989 
Anti -pan CD44 (IM7.8.1) ATCC 
Anti-Bcl2 Becton Dickinson 
Anti-CD11c Becton Dickinson 
Anti-CD18 Becton Dickinson 
Anti-CD29 Becton Dickinson 
Anti-CD34 Becton Dickinson 
Anti-CD44v6 Bender Medsystems 
Anti-CD49d (PS/2) ATCC 
Anti-CD51 Becton Dickinson 
Anti-CD54 (YN1/1.7.4) ATCC 
Anti-CD62E Becton Dickinson 
Anti-CD62L Immunotools 
Anti-CD62P Becton Dickinson 
Anti-CD117 Becton Dickinson 
Anti-CD123 Becton Dickinson 
Anti-CD127 Becton Dickinson 
Anti-IL-3 Becton Dickinson 
Anti-IL-7 Bio Trend 
MATERIALS & METHODS 
                                                                    
                    
                                                                      43 
Anti-IL-3R Becton Dickinson 
Anti-IL-7R Becton Dickinson 
Anti-pAkt Becton Dickinson 
Anti-akt Becton Dickinson 
Anti-pERK1/2 Santacruz Laboratory 




Anti-pLck Becton Dickinson 
Anti-Lck Becton Dickinson 
Anti-Ly6 Becton Dickinson 
Anti-Ter119 Becton Dickinson 
Anti-pZAP70 Cell signaling 
Anti-Zap70 Becton Dickinson 
 
2.1.5 Secondary antibodies 
Name Company 
Anti-mouse IgG HRP Amersham 
Anti-rabbit IgG HRP Amersham 
Anti-rat IgG HRP Amersham 
Anti-mouse IgG PE Jackson Laboratories 
Anti-hamster IgG FITC Jackson Laboratories 
Anti-mouse IgG FITC Jackson Laboratories 
Anti-mouse IgG APC Jackson Laboratories 
Anti-rat IgG FITC Jackson Laboratories 
Anti-rat IgG PE Jackson Laboratories 
Anti-rat IgG APC Becton Dickinson 
Streptavidin FITC Jackson Laboratories 
Streptavidin PE Jackson Laboratories 
Streptavidin APC Jackson Laboratories 
Streptavidin HRP Rockland, PA 
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MEK1/2 Inhibitor (SL327) - Calbiochem 
PI3K Inhibitor (Ly249002) - Calbiochem 
 
2.1.7 Instruments 
Common Name Company  Company name 
Agitator for Bacterial 
cultures 
Infors HT  
Beta-counter harvester Tomtec/Perkins Elmer  
Beta-counter reader LKB Wallace 1205 betaplate 
Developer(Autoradiograp
hy) 
Amersham Hyper processor 
Eagle eye Herolab Mididoc 
ELISA plate reader Anthos labtec Reader 2001 
FACS Becton-Dickinson FACS Calibur 
Microscope Zeiss  
Microscope (Inverse) Leica  
PCR cycler Eppendorf Master cycler 
pH meter Knick F61-calimatic 
Spectrophotometer Spectronic unicam Genesis 10UV 
Sonicator Bandelin Sonoplus 
Tabletop centrifuge Hereaus Biofµge 15 
Centrifuge Sorval RC 5B Plus 
Centrifuge Beckman J6B 
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2.1.8 Miscellaneous Materials 
 
Material Company 
Autoradiography films Amarsham Biosciences 
Culture flasks 25, 75 cm3  Cellstar 
Filters (0.2um) Renner GMBH 
Nitrocellulose membrane Amarsham Biosciences 
96-well microtitre plates (flat & round 
bottomed) 
Grainer bio-one 
Tissue culture plates (6 & 24 well) Grainer bio-one 
Whattmann paper Sartorius 
CFSE Invitrogen 





Acetic acid min.99.8% Riedle-de-Haen 
Annexin V- FITC Becton Dickinson 
Acrylamide/Bisacrylamide Roth 
Agarose-low grade Sigma 
Ammoniumperoxidisulphate (APS) Roth 
Biorad Protein assay reagent Biorad 
Bovine serum albumin PAA 
Bromophenol blue sodium salt e.a. Thomas GMBH 
Copper (II) sulphate  Merck 
Coomassie brilliant blue Merck 
Diethyl pyrocarbonate (DEPC) SIGMA 
Dimethylsulphoxide (DMSO) Merck 
Deoxynucleotidyltriphosphate(dNTP) Invitrogen 
ECL reagent Amersham bioscience 
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Ethanol absolute Riedle-de-Haen 
Ethidium bromide ultrapure BRF lifesciences 
Fetal calf serum PAA 
Folin Ciocalteu phenol reagent Merck 




ImProm-II reverse transcriptase and buffer Promega 
Potassium Chloride Applichem 
Propidium Iodide R & D Systems 
Potassium Dihydrogen Phosphate (KH2PO4) Merck 
Ladder prestained protein Fermantas 




Thomas Chemikalian GMBH 
Methanol Fluka 
Milk Powder Roth 
Natrium Hydroxyphosphate (Na2HPO4) Merck 
Natrium Fluoride SIGMA 
RPMI-culture medium SIGMA 
Sodium Azide (NaN3) Applichem 
Sodium Carbonate anhydrous (Na2CO3) Fishcer Scientific 
Sodium Hydrogen Carbonate (NaHCO3) Applichem 
Sodium Chloride (NaCl) J.T.Baker 





Taq polymerase and buffer SIGMA 
Tri-reagent SIGMA 
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Tris Roth 








10mM HEPES pH7.4, 140nM NaCl, 25mM CaCl2 
Bicarbonate buffer 
pH 9.6 
15mM Na2CO3, 35mM NaHCO3. Fill to 900ml with distilled 
water. Adjust pH to 9.6 and make it upto 1l with water. 
Blot buffer (5x) 10g SDS, 142g Glycine, 30.3g Tris base and make upto 1l 
with distilled water. 1X buffer was made fresh by taking 5x 
Blot buffer, methanol and distilled water in the ratio 1:1:3 
DEPC water 200µl DEPC reagent in 1l distilled water and autoclave 
Ethidium Bromide 0.2g Ethidium bromide, distilled water 20ml. Stored in 
dark. 
Freezing medium 90%FCS, 10%DMSO 
Glycine solution 0.2M glycine in PBS 
HEPES buffer 25mM HEPES pH7.2, 150mM NaCl, 5mM MgCl2, 1mM 
PMSF, 1x Protease inhibitor, 1mM NaVO4, detergent as 
indicated in experiments 
LB medium 10g Peptone, 5g Yeast extract, 10g NaCl, fill upto 1l with 
Distilled water. For LB plates 15g agar was added. 
PBS (pH7.2) 137mM NaCl, 2.7KCl, 4.3mM Na2HPO4 in distilled water 
  
Running buffer for 
protein gels (10x) 
 10g SDS, 144g Glycine, 30g Tris, filled upto 1l with 
distilled water 
TAE Buffer 242g Tris base, 57.1ml Glacial acetic acid, 100ml 0.5m 
EDTA pH 8.0, Add distilled water 1l and adjust final pH to 
8.5.  
TNES buffer 50mM Tris, 0.4M NaCl, 100mM EDTA, 1% SDS. 
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2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 RNA preparation, cDNA synthesis and amplification 
Total RNA was prepared from 107 cells with Tridy reagent preparation following 
manufacturer’s instructions (Applichem, Darmstadt, Germany). Quality of RNA 
preparation was checked by running RNA sample diluted in RNA sample buffer on 
1% agarose/formaldehyde gel. 
cDNA synthesis and amplification was performed by RT–PCR (reverse transcriptase 
polymerase reaction). 1-2 µg template RNA was mixed with 0.5µg oligo dT primer 
and heated at 70°C, 5 min; chilled on ice, then mixed with 1µl Im Prom II reverse 
transcriptase (10U), 1-2mM dNTP, 1x Im Prom II buffer 5x, 6mM MgCl2 and made 
upto a total of 20µl with nuclease free water.The program continues as 25°C-5min, 
42°C-60min and 70°C-15min. 
PCR was performed in 25 µl volume containing template, 1-2 mM dNTP, 1.5µl Red 
Taq polymerase, 2.5 µl 10x Taq buffer and 0.2 µM primer forward and reverse. Total 
volume was completed to 25 µl with autoclaved distilled water. 
PCR Program: 
CD44s : 94°C-5min, 94°C-30secs, 55°C-30secs, 72°C-1min -32cycles, 72°C-10min 
 
CD44v6 : 94°C-5min, 94°C-30secs, 53°C-30secs, 72°C-1min -32 cycles, 72°C-10min 
 
CD44v7 : 94°C-5min, 94°C-30secs, 52°C-30secs, 72°C-1min -32 cycles, 72°C-10min 
 
CCR9 & CCL25 : 94°C-5min, 94°C-30secs, 69°C-30 secs, 72°C-1min -32cycles, 
72°C-10min 
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2.2.1.2 DNA gel electrophoresis 
 
PCR products or samples containing DNA of interest were checked by running an  
agarose gel of 1-2%, depending on the size of the product. When Red Taq 
polymerase was not used then DNA sample was mixed with loading dye (6x) to 
locate the running front. Markers (1kb or 100bp) were run in parallel. The gel was run 
at 100 volts in a migration tank containing 1x TAE buffer. Bands were visualized on a 
U.V. transilluminator. 
 
2.2.2 Protein Chemistry 
2.2.2.1 Antibody purification 
 
Hybridoma supernatants were purified by passing around 1-2 l of supernatant over 
Protein-G Sepharose column (Pharmacia). The column was washed with 0.1M 
phosphate buffer, pH 7.5. Bound IgG was eluted from the column with 0.1M Glycine 
buffer pH 2.7. Protein containing fractions were dialyzed against PBS, concentrated 
and filter-sterilized. The protein amounts obtained were photometrically analysed for 
protein concentration by Folin test. 
 
2.2.2.2 Folin test (Protein concentration determination) 
Based on the Lowry test, this method aims at detecting cuprous ions by Folin-
Ciocalteu reagent. In this assay a protein (antibody) solution is mixed with an alkaline 
solution of copper salt. Under these conditions cupric ions chelate with peptide bonds 
resulting in reduction of cupric ions (Cu2+) to cuprous ions (Cu+). Cuprous ions can 
be detected by reduction of the Folin-Ciocalteu reagent which produces blue colour 
that can be read at 748 nm. A blank solution with only PBS and BSA standard 
dilutions of 0.5 mg/ml and 1mg/ml were used for calibration. Assays were done in 
duplicates. From each sample 50µl were mixed to 1ml alkaline solution containing 
Cu2+ ions. Then 100µl of Folin Ciocalteu reagent was diluted 1:1 in water and added 
to each sample. The samples were agitated for 20 minutes at RT and read at 748 
nm. 
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Sample concentration mg/ml: F*10’mean sample OD748 
F= A+B/2           A:500/(mean OD standard 500µg/ml *103) 
                            B:250/(mean OD standard 500µg/ml *103) 
 
2.2.2.3 SDS- polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein components were separated using SDS polyacrylamide gel electrophoresis 
(SDS-PAGE). SDS, an anionic detergent denatures and imparts negative charge to 
all proteins in the sample. Proteins can be separated according to their size in an 
electrical field.  Two gels were used for this purpose. At the bottom resolving gel was 
poured to separate the proteins and at the top a stacking gel. The stacking gel 
concentrates all proteins in one band and allows them to enter the resolving gel at 
the same time; it can be mounted with a comb to load samples in the wells.  Before 
loading the gel, samples were boiled for 5 minutes at 95° C for proteins to allow 
complete protein denaturation. Around 25-30 µl of sample was loaded into wells. The 
inner and outer chambers were filled with running buffer (1x). 
 
2.2.2.4 Western Blotting 
Following gel electrophoresis, proteins were electroblotted onto a nitrocellulose 
membrane (Amersham Biosciences) overnight at 30 volts and analysed by 
immunoblotting using specific primary and secondary antibodies. The gel, foam pads 
and 3MM Whattmann papers were equilibrated in blotting buffer; the gel was placed 
on the membrane which in turn was placed on Whattmann paper followed by foam 
pads on either side. The whole set was placed in a cassette holder, followed by a 
tank blotting apparatus such that the membrane was placed towards the anode side. 
After overnight transfer, the blots were blocked with PBS/5% Milk powder or BSA (for 
phosphospecific antibodies) for 1 hour, followed by primary antibody for 1 hour. Blots 
were washed with PBS/0.1%Tween thrice and 5 minutes each wash. Then the blots 
were  incubated  in  secondary a ntibody for an hour, followed by washing again. The  
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blots were developed with Enhanced Chemiluminescence system (ECL, Amersham 
Biosciences) and exposed to X-ray film (Amersham Biosciences) for desired time 
points and developed. 
 
2.2.3 Cell biology 
2.2.3.1 Cell Culture 
 
Cells were grown in a humidified incubator at 37°C, 5% CO2. Cells were maintained 
in RPMI or DMEM medium in 10% FCS as per the requirements and split when they 
reached confluency. Cells were usually passaged at a ratio of 1:4. Trypsin (0.25%) 
(w/v) in PBS was used to disperse adherent cells and reseeded to fresh culture 
flasks. 
 
For long term cell storage, cells were washed once with medium and frozen in 
cryovials in FCS, 10% DMSO. The vials were placed for 1 hour at -80°C before 
transferring into liquid nitrogen. Cells were thawed from the cryovials by placing the 
vials from liquid nitrogen first on ice, followed by 37°C water bath and immediately 
placed in falcon containing medium and centrifuged at 1600 rpm for 5 minutes. The 
medium was sucked off and new medium was added and transferred to flasks at high 
density to maximise recovery. 
 
Cell viability was determined using hemacytometer and trypan blue staining. 
Trypan blue (2x): 0.4% Trypan blue (4vol) 
                             4.5% NaCl (1vol) 
 
2.2.3.2 Magnetic Beads separation 
 
BMC were T cell-depleted by panning on Petri dishes coated with a mixture of anti-
CD4 and anti-CD8 collecting the non-adherent fraction (purity: <2% CD4+ and CD8+ 
cells).  Lin- cells  were  enriched  by  incubation  with  biotinylated  anti-Ter119, DX5,  
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Ly6C/G, CD3, CD8, CD11c and CD19 followed by incubation with streptavidin-
conjugated magnetic beads (Miltenyi) collecting the non-adherent fraction. CLP1 (c-
kit+B220-) and CLP2 (c-kit-B220+) cells were derived from lin- cells by incubation with 
the respective magnetic bead-coated antibodies. DP (CD4+CD8+) and DN  (CD4-
CD8-) thymocytes (TC) were enriched by magnetic bead sorting using magnetic-
bead-coated anti-CD4, followed by magnetic bead-coated anti-CD8 (regain of DP TC 
~60%, regain DN TC ~5%, purity ~95%-98%). DN TC were enriched for DN1 
(CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-CD25+) and DN4 (CD44-CD25-) by 
incubation with anti-CD44 followed by anti-rat IgG-coated magnetic beads. Adherent 
and non-adherent fractions were further separated by incubation with anti-CD25-PE 
and anti-PE-coated magnetic beads or biotinylated anti-CD25 and streptavidin-
coated magnetic beads (regain: <1%, purity ~85%-95%). Where indicated, cells were 
labeled with CFSE (Molecular Probes). 
 
Donor- and host-derived CD8+ T cell from the spleen were prepared by negative 
selection. CD8+ cells were subsequently incubated with biotinylated anti-H-2b or anti-
H-2d and Streptavidin-coated magnetic beads (regain of donor- and host-derived 




Immunoreactivity was evaluated by the analysis of IFN-γ expression (flow cytometry) 
and cytotoxic T lymphocyte activity. The cytotoxicity assay was performed according 
to the JAM-Test (Just Another Method) method described by Matzinger [172]. The 
assay measures DNA fragmentation. Target cells were labeled with 3H thymidine to a 
final concentration of 2.5 to 5 µCi/mL for 4 to 6 hours. They were then pelleted, 
washed once with culture medium, and distributed in triplicates (104 cells per well) 
into 96-well round-bottomed microwell plates. After adding effector cells in 
appropriate dilutions as mentioned in results, the plates were incubated in a 
humidified atmosphere at 5% CO2 for 6 hours approximately. The cells and medium 
were than aspirated onto fiber glass filters using a cell harvester. After washing and 
drying  the  filters, they  were  placed  in  liquid  scintillation  fluid, sealed and counted  
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using a liquid scintillation β-counter. The radioactivity measured corresponds to intact 
DNA, since DNA from dead cells is degraded into small fragments that pass through 
the filter. For calculating % specific killing, the standard formula for the JAM test is: 
% specific killing = (S-E)/S 100, with E = experimentally retained DNA in the presence 
of effector cells (in cpm) and S = retained DNA in the absence of effector cells 
(spontaneous). 
 
2.2.3.4 Flow Cytometry 
Fluorescent activated cell sorting (FACS) allows cell segregation based on size and 
volume and also allows detecting expression levels of proteins in cells. This method 
is based on diffraction of light and measure of fluorescence which reflects cell size 
and amount of fluorescent antibody labeled cells. 
Cells were washed in PBS/0.5% BSA. About 5x105 cells were added to round 
bottomed 96 well plates. After centrifugation cells were suspended in 50 µl of primary 
antibody diluted in PBS/0.5% BSA and incubated for half an hour on ice. This was 
followed by washing the cells thrice with PBS/0.5%BSA, 5min each wash. Secondary 
antibody (50µl) coupled to fluorochrome was added to each well and incubated for 
half an hour on ice in the dark. The cells were again washed. After the last wash cells 
were suspended in 200µl PBS/0.5%BSA for immediate measuring. Staining was 
evaluated using FACS-Calibur (Becton Dickinson, Heidelberg, Germany).  In case of 
double or triple fluorescence the same procedure was repeated with adequate 
antibodies and blocking steps wherever necessary (e.g. different antibodies from the 
same species). 
 
For cytokines, intracellular FACS was performed. The cells were first incubated with 
formalin 1% to fix them for 10 minutes on ice. The cells were washed with PBS 
1%BSA 3x as mentioned above. Thereafter the cells were incubated with 0.1 % 
Tween for 15 minutes on ice to create pores on the cell membrane and facilitate the 
entry of antibodies against the cytokines into the cells. The cells were again washed 
and antibodies were added following the usual protocol. 
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2.2.3.5 Proliferation assay 
3H-Thymidine incorporation was used to measure DNA synthesis. Thymocytes 
(2x105) were seeded on flat bottomed 96 well plates that were pre-coated with anti-
CD3 alone, anti-CD44/CD44v6 alone or both and isotype control antibody. All assays 
were run in triplicates. Cells were cultured in RPMI 1640 complete medium for 48 
hours. 3H-thymidine (10µCi/ml) was added after 48 hours and cultures were 
maintained for an additional 16 hours. Thereafter the cells were harvested by vacuum 
onto glass fibre filters. During this step free 3H-thymidine was washed through the 
filters and incorporated 3H-thymidine was retained in the DNA. This radioactivity 
retained in the filters was measured by liquid scintillation counting in a β-counter.    
 
2.2.3.6 Apoptosis Assay 
Apoptosis assay was performed using Annexin V-FITC and propidium iodide (PI) (R 
& D systems, Wiesbaden-Nordenstadt, Germany) double staining. Early apoptotic 
cells bind to Annexin V because of the exposed phosphatidylserine on the outer cell 
membrane. Late apoptotic cells are positive for Annexin V and PI. Necrotic cells bind 
only PI. Thymocytes (2x105/well) were seeded on flat bottomed 96 well plates that 
were pre-coated with anti-CD3 alone, anti-CD44/CD44v6 alone or both and isotype 
control antibody. All assays were run in triplicates. Cells were cultured in the 
incubator for 12, 24 or 48 hours. After the desired time points plates were centrifuged 
at 1600 rpm for 5 minutes and washed with PBS/1% BSA. Cell labelling was 
performed according to manufacturer’s instructions. Cell were incubated in the dark 
at RT for 15 min and detected by FACS using the FL1 channel for Annexin FITC and 
FL-3 channel for PI. 
 
2.2.3.7 Thymocytes Stimulation and Activation 
 
Thymocytes were stimulated by antibody cross-linking. Flat bottomed-96 microwell 
plates or 60mm cell culture dishes were coated with indicated concentrations of 
antibodies overnight at 4°C. Bicarbonate buffer at pH 9.6 was used for coating. Anti- 
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CD3 (1 µg/ml), anti-CD44/CD44v6 (10µg/ml) or both and control IgG antibodies were 
used for coating. Plates were washed with PBS several times and blocked with 
PBS/1% BSA for 1 hour at 37°C, 5% CO2. Thereafter, plates were again washed 
several times with PBS and kept at 4°C until use. 
 
For short term signaling experiments (tyrosine phosphorylation, ERK1/2, MEK1/2, 
Lck, ZAP-70 and Akt activation) 40µl of 5x105 -106 cells in RMPI1640 were added to 
control and antibody coated plates. Cells were kept at 37°C, 5% CO2 for 18 minutes. 
Thereafter, 20µl of reducing Laemmli buffer was added to each well to stop the 
reaction and to lyse the cells followed by sonication to destroy the DNA. The samples 
were frozen till they were loaded onto the gel. Cells were incubated over night on 
antibody coated plates to detect apoptotic and anti-apoptotic proteins. 
 
2.2.4 Animal Experiments 
2.2.4.1 Preparation of hematopoietic cells 
  
Mice were killed by cervical dislocation. Thymi and spleen were removed aseptically 
and placed in medium. They were then placed on a petri dish with fine gauze and 
meshed carefully to release the thymocytes. Bone marrow cells (BMC) were obtained 
by flushing femur and tibia with PBS and meshed like before.  The cell suspension 
was washed several times before adding medium. For short term signaling 
experiments of thymocytes RPMI without FCS was used. For long term culture 
periods between 1-5 days complete RPMI medium was used. 
 
2.2.4.2 Reconstitution, tumour implantation and vaccination 
 
For experiments with allogeneic bone marrow transplantation, irradiated BALB/c mice 
received i.v. injections of anti-asialo GM1 every 2 wk for NK cell depletion. Mice were 
reconstituted with 2x106 Tdepl SVEV BMC 24 h after irradiation. Where indicated mice 
received 2x105 DP TC from SVEV mice. IL-3 (1µg / mouse) and IL-7 (1.5µg /  
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mouse) were given i.v. twice weekly. Mice received s.c. application of RENCA 
(5x104), YC8 / YC8.lacZ (1x102) or Sp6 (2x103) cells 5 days after reconstitution. The  
tumor dose corresponds to 5x the minimal dose for 100 % tumor take in non-
manipulated, syngeneic BALB/c mice. For vaccination, mice received 1 wk after 
tumor cell application s.c. injection of YCA. LacZ lysate plus ß-Gal (100µg) or of Sp6 
lysate plus Sp6 IgM (200µg) in adjuvant. For short term reconstitution, Tdepl BMC 
(1x107/mouse) and DP TC (5x106/mouse) were CFSE-labeled. Cells were labeled 
with 2-3 µM CFSE for 10-15 min, then washed several times with PBS and used for 
injections. CFSE (Carboxyfluorescein succinimidyl ester) is a fluorescent cell labeling 
dye which gets diluted through every cell division and intensity of the dye on cells can 
be measured by FACS to check the percentage of migrating cells into the bone 
marrow, spleen and thymus after intravenous (i.v.) injections into mice. Mice were 
sacrificed after 18h-120 h.   
 
For experiments dealing with thymocyte maturation lethally irradiated BALB/c (8Gy) 
or SVEV (9.5Gy) mice were i.v. reconstituted with 5x106 BMC or BMC/TC 
subpopulations, 24h after irradiation. Some mice in addition received i.v. injections of 
100µg anti-CD44 (IM7) or rat IgG (control), twice per week starting at the day of 
reconstitution. For short term reconstitution, mice received an i.v. injection of 1x107 
CFSE-labeled BMC and/or 1-5x106 BMC or TC subpopulations, as indicated in the 
individual experiments. Mice were sacrificed at the indicated time points, SC, BMC 
and TC were isolated and the recovery of fluorescent cells was evaluated by flow 
cytometry. Depending on the percentage of fluorescent cells, up to 100,000 events 
were collected. Animal experimentations were approved by the governmental 
authorities of Baden-Wuerttemberg, Germany. 
 
2.2.4.3 Graft vs Host Disease (GVHD), graft rejection and tumor growth 
 
Evidence for GVHD was obtained by weight loss and macroscopic inspection of skin, 
gut and liver. Graft rejection was defined by flow cytometry of host and donor-derived 
cells in central and peripheral lymphoid organs and the absence of donor-derived 
cells. Tumor growth was evaluated twice per week (mean tumor diameter) and 
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surveying for signs of rejection. Animals with (bloody) diarrhoea, cachexy and >25% 
weight loss or with a tumor of 2 cm diameter were sacrificed (survival time). 
 
2.2.5. Statistical analysis  
 
Significance of differences was calculated according to the Wilcoxon rank sum test 
(in vivo assays) or the Student's T test (in vitro studies). Functional assays were 
repeated at least 3 times. Mean values and standard deviations of in vivo 
experiments are derived from 3-5 experiments with 8-10 mice / group in the individual 
experiments. Accordingly, mean ± SD are mostly derived from 24-50 mice / group. 
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3.Results 
 
We are particularly concerned with improvement of thymic reconstitution including 
establishment of tolerance induction towards the host after allogeneic bone marrow 
cell reconstitution of tumor bearing host. For this purpose I first evaluated the 
importance of allogeneic bone marrow transplantation (BMT) on B and T lymphoma 
bearing mice as described in detail below.  
 
3.1 T and B Lymphoma bearing mice show poor repopulation of 
thymus 
 
It has been shown in our lab using a renal cell carcinoma model that host NK cell 
depletion favors acceptance of allogeneic T cell depleted (depl) BMCs in 
myeloreductively conditioned host. In the first few weeks after reconstitution, 
repopulation of the thymus was poor but in the later weeks donor-derived bone 
marrow cells dominated and were also host tolerant [173]. We checked whether 
these observations would also hold true for leukemia bearing mice. Irradiated (6Gy) 
and NK depleted Balb/c mice received T cell depleted (depl) bone marrow cells, from 
SV129 together with tumor application of YC8/YC8.LacZ (T lymphoma) or SP6 (B 
lymphoma) both being of Balb/c origin. It was observed that less spleen cells were 
recovered in tumor bearing mice after 2 weeks as compared to tumor free mice.  The 
difference had vanished after 8 weeks. However, in the thymus much lesser cells 
were recovered in the tumor bearing mice as compared to tumor free host (Fig.1A). 
When the percentage of donor derived cells were checked it was seen that from the 
spleen in the first 2 weeks much lesser donor-derived cells were obtained as 
compared to tumor free mice and after 8 weeks (wks) the difference though less 
pronounced was still visible. In the thymus the number of donor derived cells 
remained low during the observation period of 2 and 8 weeks in lymphoma bearing 
mice as compared to tumor free mice (Fig.1B). Evaluating donor derived T cells 
revealed that both CD4 and CD8 T cells were lesser in spleen after 2 and 8 weeks in 
tumor bearing mice. In the thymus CD4+CD8+ (DP) cells were much lesser in the  
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lymphoma bearing mice than the tumor free mice (Fig.1C). A very high number of 
lymphoma bearing mice suffered from GVHD (Fig.1D). 
 
Cytotoxic assay was performed to look for anti-donor, anti-host and anti-tumor 
activities using host CD8 T cells and donor CD8 T  against donor spleen cells , host 
spleen cells  and tumor lysates respectively. It was observed that anti-host activity 
was very high throughout and no significant anti-tumor activity was seen. No 
significant difference in anti-donor activity was observed (Fig.1E).  There was no 
significant difference observed in the number of surviving lymphoma bearing mice, 
between lymphoma bearing mice receiving syngeneic reconstitution in comparison to 
allogeneic reconstitution (Fig.1F& G).  
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Fig. 1 Repopulation of the thymus in the lymphoma-bearing mouse 
Irradiated (6Gy) and NKdepl BALB/c mice were reconstituted with 2x106 Tdepl SVEV BMC. Mice 
received a s.c. injection of 2x101 YC8 or 4x102 Sp6 cells, 5d after reconstitution (A) The number of 
SC and TC was evaluated 2 and 8 wk after tumor cell application; (B) The percentage of donor-
derived SC and TC and (C) of donor-derived T cells was evaluated by flow cytometry; (A-C) Mean 
values±SD of 3 independently performed experiments; significant differences as compared to tumor-
free mice are indicated by an asterisk (D) The percentage of mice that were sacrificed due to severe 
GVHD; The actual number of mice is given in brackets. Significant differences as compared to tu-
mor-free mice are indicated by an asterisk; (E) SC were collected 4, 6 and 8 wk after tumor cell 
application. Cells were restimulated in vitro with irradiated donor or host lymphocytes or the 
corresponding tumor cells for 8d. Cytotoxic activity against the target used as stimulator during 
restimulation was evaluated at E:T = 25:1. For the evaluation of anti-tumor reactivity, host-derived 
lymphocytes were added as cold target (T:cT = 1:10). Values represent the mean±SD of triplicates; 
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BALB/c or SVEV mice received 1x102 YC8 or 2x103 Sp6 cells. The survival time of mice developing 
tumors is shown (Mice sacrificed because of severe GVHD were excluded). Differences between 
syngeneically and allogeneically reconstituted mice were not significant.  
 
  
Thus, T and B cell lineage derived malignancies hampered the process of thymus 
repopulation. The few donor-derived T cells in the periphery obviously were not 
tolerant towards the host, as a considerable percentage of mice succumbed with 
severe GVHD, and T cells of the remaining mice developed strong cytotoxic activity 
against host lymphoblasts. These unexpected results indicated i. that the thymus 
becomes repopulated rather late after reconstitution with Tdepl BMC, and ii. that at 
such a late state, hematopoietic tumors may compete with T progenitor cells for 
thymus repopulation. The failure to achieve a timely appropriate repopulation of the 
thymus demanded an elaboration of alternative reconstitution protocols. 
 
3.2 Continuous application of cytokines (IL-3 and IL-7) promotes 
expansion of donor and host cells in thymus and spleen 
 
The cytokines IL-3 and IL-7 provide as major growth factors for B and T cells. 
Application of cytokines induces proliferation of thymocytes especially in the early 
stages as well as increases the peripheral T cell output [60, 174]. 
So, we included application of cytokines in our protocol, to check if they were able to 
improve reconstitution and increase the numbers of donor derived cells homing into 
thymus. Mice received i.v. injections of IL-3 and IL-7 after BMCT. It was seen that 
reconstitution improved in mice after receiving cytokines especially in spleen cells 
(SC) and to some extent in thymocytes (TC) (Fig.2A). However, the percentage of 
donor derived cells was still less in thymus even after receiving cytokine injections 
(Fig.2B). Anti-donor and anti-host cytotoxicity remained high through out the period 
observed (Fig.2C). The survival rate of mice also remained the same even after IL-3 
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Fig. 2  IL-3 and IL-7 support maturation of host and donor progenitor cells 
 BALB/c mice were conditioned and reconstituted as described in Fig.1. Mice received, in addition, IL-
3 plus IL-7, twice per week, starting at the day of reconstitution. Tumor cells (2x101 YC8 or 4x102 
Sp6). were injected 5d after reconstitution (A) Number of SC, TC and BMC at 2 and 8 weeks after 
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independently performed experiments; significant differences between mice receiving or not receiving 
IL-3 plus IL-7 are indicated by an asterisk; (C) Cytotoxic activity against donor and host cells was 
evaluated as described in Fig 1. Values represent the mean±SD of triplicates; (D and E) BALB/c mice 
conditioned and reconstituted as described above, received 1x102 YC8 or 2x103 Sp6 cells. The 
survival time and rate are shown (Mice sacrificed because of severe GVHD were excluded). 
Differences between mice receiving or not receiving IL-3 plus IL-7 were not significant. 
 
 
We concluded that in the myeloreductively conditioned host, IL-3 and IL-7 provided a 
growth stimulus that, however, accounted for host and donor lymphoid progenitors. 
Therefore we next asked, whether weakening the host hematopoietic system may 
provide a growth advantage for donor BMC. 
 
 
3.3 Donor derived hematopoietic progenitor cell expansion can be 
improved by strengthening the myeloreductive conditioning 
 
Since strengthening the myeloreductive conditioning increases the number of donor 
cells in the host during reconstitution [175] we thought of increasing radiation dose to  
7Gy hoping to see more donor cell expansion in the host. The theory behind it is, 
increasing the radiation dose kills more host cells and the host would rely more on 
the donor hematopoietic cells for expansion and differentiation. 
 
Balb/c mice were irradiated with 6Gy or 7Gy and treated with anti-asialoGM1, for host 
NK cell depletion. In addition mice received BMT depleted of T cells from SVEV mice 
and Sp6 tumor cells. Where indicated injections of IL-3 and IL-7 were given twice per 
week. The percentage of donor derived cells recovered in host SC and TC was more 
after myeloreductive strengthening (7Gy) (Fig.3A). The percentage of donor derived 
T cells was then calculated. In the spleen a higher percentage of CD4 cells were 
recovered after 7Gy and IL-7 injections after 2 and 6 weeks. There was no change in 
CD8 T cells. In the thymus higher donor derived DP (CD4+8+) thymocytes were 
recovered, which could be distinguished clearly after 2 weeks of transfer (Fig.3B). 
IFN-γ expression was checked as a marker for cytotoxic T cell activity [176]. The 
expression of IFN-γ by donor T cells decreased in mice receiving 7Gy irradiation and 
in addition after receiving IL-7 injection significantly after 6 weeks (Fig.3C). There  
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was also lesser cytotoxicity against the donor and host observed especially after 6 to 

























Fig. 3 Stronger myeloreduction improves donor cell expansion 
 NKdepl BALB/c mice were conditioned with 6Gy or 7Gy. Mice were reconstituted as described in 
Fig. 1 and received, in addition, IL-3 plus IL-7, twice per week, starting at the day of reconstitution 
(A) The percentage of donor-derived SC and TC, (B) the percentage of donor-derived splenic T 
cells and donor-derived DP TC and (C) the percentage of donor or host-derived IFNγ-expressing 
SC was evaluated by flow cytometry. Mean±SD of 3 independently performed experiments; signifi-
cant differences between mice conditioned with 6Gy or 7Gy are indicated by an asterisk; (D) 
Splenic host- and donor-derived T cells were isolated by magnetic bead sorting (purity: >90%). Do-
nor- and host-derived T cells were cultured with irradiated host or donor lymphocytes for 8d. 
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Values represent the mean±SD of triplicates; 8wk after reconstitution, anti-host reactivity was 
significantly lower in 7Gy than 6Gy conditioned mice (indicated by an asterisk). 
 
Thus, even a minor increase in the percentage of donor-derived progenitor T cells in 
the thymus sufficed for a reduction in GVHD and host-directed cytotoxicity. Because 
7Gy were not lethal, i.e. reconstituted mice survived, we proceeded with the stronger 
myeloreductive regimen to support repopulation of the thymus. 
 
 
3.4 Immature double positive (DP) thymocytes from donor 
preferentially home into the host thymus 
 
We hypothesized that the problem of GVHD could be partially solved by injecting 
early thymocytes along with donor BMCs. In this case the thymocytes would mature 
in the host thymus and hence would be host tolerant as well as have the ability to kill 
the tumor [4]. So we performed the experiments using DP thymocytes. In the 
following experiments Balb/c mice were NK depleted and conditioned with 7Gy 
followed by injections of 107 CFSE labeled T depleted BMC or 107 CFSE labeled T 
depleted BMC plus 5x106 CFSE labeled DP TC or unlabeled T depleted BMC plus 
labeled DP TC. To avoid overlapping spectrum from labeled dyes, the same dye was 
used to label BMCs and TCs. TCs were differentiated from BMC by staining them in 
addition with CD4-APC and CD8-PE antibodies. The recovery of CFSE labeled cells 
was recorded by FACS during the following days. CFSE labeled T depleted BMCs 
were first recovered in the spleen and then became enriched in bone marrow after 
48hrs. IL-3 and IL-7 in the absence of DP TCs had no major impact on homing into 
bone marrow and thymus. When mice received BMCs along with DP TCs a very high 
number was found to recover also in the thymus (Fig.4A). However, when different 
combinations of dye labeled BMC and DP TCs were injected it was observed that no 
CFSE labeled DP TC could be recovered from the host bone marrow (Fig.4B). In 
addition it was observed that about 34% of the cells in thymus were double positive 
for CFSE dye as well as DP TCs when CFSE labeled BMCs plus CFSE labeled DP 
TCs were used, suggesting that CFSE labeled DP TCs preferentially homed into the 
thymus. In addition when only dye labeled DP TCs were used and unlabeled BMCs it  
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was seen that the dye labeled DP TCs only homed into thymus and were not 
recovered in the bone marrow (Fig.4C).  In the spleen there was no change in the 
ratio of dye labeled T depleted BMCs and dye labeled DP TCs for the period of 120 
hrs observed. In the bone marrow very few dye labeled DP TCs almost negligible 
were recovered at 96 and 120 hours (later time points). In the thymus hardly any dye 
labeled T cell depleted BMCs were recovered. However the number of dye labeled 
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Fig. 4  Homing of Tdepl BMC and of DP TC in the myeloreductively conditioned allogeneic host  
NKdepl BALB/c mice were conditioned with 7Gy and received 2x107 Tdepl BMC or 2x107 Tdepl BMC plus 
1x107 DP TC from SVEV mice. TC or both BMC and TC had been CFSE labeled. Mice were sacrificed 
after 18h-120h (A) Both Tdepl BMC and DP TC were CFSE-labeled. The percentage of CFSE-labeled SC, 
TC and BMC was evaluated by flow cytometry; (B) Examples of the recovery of CFSE-labeled cells in 
spleen, bone marrow and thymus and (C) of CD4+CD8+ cells 96h after application of CFSE-labeled Tdepl 
BMC of CFSE-labeled Tdepl BMC plus CFSE-labeled DP TC or of unlabeled Tdepl BMC plus CFSE-
labeled DP TC (D) The percentage of dye-labeled CD4-CD8-, CD4+CD8+, CD4+CD8- and CD8+CD4- SC, 
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TC and BMC in mice that had received dye-labeled Tdepl BMC plus DP TC plus IL-7 has been evaluated 
by counterstaining with anti-CD4-APC and anti-CD8-PE (Mean values of 3 mice per group). 
 
3.5 Reconstitution of myeloreductively conditioned mice with Tdepl 
BMC plus DP TC accelerates repopulation of the periphery with 
donor-derived lymphocytes 
 
7Gy and anti-asialo GM1 conditioned mice were reconstituted with 2x106 T depleted 
BMC and 2x105 DP TC with or without IL-3 and IL-7 application. In the spleen a 
slightly higher number was recovered after DP TC application after 6 weeks and with 
the application of cytokines the number increased a little more. In the host thymus 
after 2 wk number of cells recovered was much higher after receiving DP TC along 
with BMC. There was no effect on cytokine application. The effect was normalized 
after 6wk (Fig.5A). The percentage of donor derived cells was calculated in SC and 
the numbers were higher 2 weeks after DP injections along with BMC and IL-7 
application in addition. In the thymus a very high percentage of donor cells were 
recovered after the addition of DP with BMC instead of BMC alone, with no effect on 
cytokine application (Fig.5B). 
 
When cytotoxicity was measured against the donor and host we saw that when DP 
TCs were injected along with BMC there was a significant decrease in anti-donor as 
well as anti-host activity. Application of cytokines led to a further decrease in anti-host 
reactivity with no major effect on anti-donor activity (Fig.5C).  
 
From this experiment onwards mice received vaccinations in addition, to strengthen 
the immune response against tumor. Two and four weeks after reconstitution with 
BMC plus DP TC, mice received in addition a subcutaneous (s.c.) injection of a 
mixture of tumor lysate (1x107 cells) plus tumor antigen (β- galactosidase plus 
YC8.LacZ lysate or SP6 IgM plus SP6 lysate) in adjuvant. SC were collected 1 wk 
after the challenge and cytotoxicity against host and tumor were measured using 
irradiated host and tumor cells respectively. There was a striking reduction in the 
activity against the host but the tumor activity was higher in mice that received T 
depleted BMC plus DP TC in both B and T lymphoma bearing mice (Fig.5D).  
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Fig. 5 Reconstitution of myeloreductively conditioned mice with Tdepl BMC plus DP TC accelerates 
repopulation of the periphery with donor-derived lymphocytes 
 BALB/c mice were conditioned as described in Fig.3 and were reconstituted with Tdepl BMC plus DP TC and 
received i.v. injections of IL-3 and IL-7 twice per week. Sp6 myeloma cells (4x102) were s.c. injected 5d after 
reconstitution (A) Number of SC and TC after 2wk and 6wk and (B) percentage of donor-derived cells (A and 
B). Data represent the mean±SD of 3 independently performed experiments; significant differences to mice 
receiving only Tdepl BMC are indicated by an asterisk; (C) Donor- and host-derived T cells, separated as 
described in Fig 3 were cultured with irradiated host or donor lymphocytes for 8d. Cytotoxic activity against 
donor or host cells (E:T = 25:1) was evaluated as described in Fig 1. Values represent the mean±SD of 
triplicates. Significant differences in cytotoxic activity between SC from mice receiving Tdepl BMC or Tdepl 
BMC plus DP TC are indicated by an asterisk (D) Mice reconstituted as described in (A) received s.c. 
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reconstitution. Mice were sacrificed after 5wk and unseparated SC were restimulated in vitro with irradiated 
tumor cells or host lymphocytes for 1wk. Cytotoxic activity against host lymphoblasts and YC8.lacZ or Sp6 at 
E:T = 40-5:1 is shown. Values represent the mean±SD of triplicates; significant differences between mice 
reconstituted with Tdepl BMC or with Tdepl BMC plus DP TC plus IL-3 and IL-7 are indicated by an asterisk. 
 
 
Taken together, a considerable percentage of DP TC homed into the thymus. Distinct 
to peripheral donor-derived T cells from mice reconstituted with only Tdepl BMC, 
donor-derived T cells from mice receiving DP TC, in addition, were tolerant towards 
the host, but still could respond against a tumor. Thus, this reconstitution protocol 
might allow for tumor vaccination. 
 
3.6 Lymphoma growth retardation and rejection in the 
myeloreductively conditioned mouse reconstituted with T depleted 
BMC and DP TC 
 
In order to check if BMC transplantation along with injection of DP TC supports a 
tumor vaccination protocol in lethally irradiated mice, animals were reconstituted and 
received along with tumor application of Sp6, an s.c. injection of SP6 cell lysate plus 
SP6 IgM in adjuvant. Vaccination was repeated every 2 wk. 
 
From 21 mice receiving T depleted BMC plus DP TC only 1 mouse/group developed 
GVHD showing that DP TC do not induce high GVHD, which is always a threat in the 
reconstitution protocol. After vaccination 6/21 mice reconstituted with T depleted 
BMC died of GVHD and 2/21 reconstituted with T depl BMC plus DP TC died of 
GVHD (Fig.6A). The number of SC counted were lowest in T cell depleted BMC 
reconstitution followed by T cell depleted BMC plus vaccination, T cell depl BMC plus 
DP TC and the highest numbers in SC was recovered in mice receiving T cell depl 
BMC plus DP TC plus vaccination (Fig.6B). The percentage of  CD4 T cells 
recovered in SC was  highest after vaccinating mice receiving DP TC and BMC, 
followed by no vaccination, mice receiving vaccination and BMC alone without TC 
and lastly mice receiving no vaccination and BMC alone (Fig.6C). T cell depl BMC 
reconstituted mice that received vaccination had the highest expression of IFN-γ 
which decreased significantly in T cell depl BMC plus DP TC reconstituted mice  
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receiving vaccination (Fig.6D). As the next step anti-host and tumor activity were 
measured using SC from the host (effector) and host lymphoblasts and tumor cells as 
target. The anti-host activity was reduced to a great extent in mice receiving DP TC 
with or without vaccination. The anti-tumor activity was high only in the case of DP 
TC mice receiving vaccination (Fig.6E). The survival rate of mice was calculated. 
Mice receiving vaccination after reconstitution had higher survival rates in general. 
Mice reconstituted with DP TC had almost 80% survival rate after tumor vaccination 
(Fig.6F). 
 
Fig. 6 GVHD and GvT reactivity in myeloablatively conditioned mice reconstituted with Tdepl BMC plus DP               
TC and vaccinated with tumor cells 
 BALB/c mice received 8Gy and anti-asialoGM1 and were reconstituted as described in Fig.5. They 
received a s.c. injection of a mixture of Sp6 lysate (corresponding to 1x107 cells) and Sp6 IgM (150µg / 
mouse). in adjuvant at the day of Sp6 cell inoculation. Vaccination was repeated after 2wk (A) The 
percentage of mice succumbing with severe GVHD is shown (B-E) The following parameters were 
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percentage of CD4+ and CD8+ SC (flow cytometry).; (D) the percentage of IFNγ expressing SC (flow 
cytometry) and (E) cytotoxic activity of SC against host lymphoblasts and Sp6 tumor cells evaluated as 
described in Fig 1. The % cytotoxicity at an E:T ratio = 50:1 is shown (F) The percentage of tumor-free 
mice 80d after reconstitution is shown (A-F) Significant differences as compared to mice reconstituted 
with Tdepl BMC are indicated by an asterisk. 
 
 
It is known that only non-myeloablative or myeloreductive conditioning is comparably 
well tolerated by patients with hematological malignancies [177]. Hence, we repeated 
the experiment in a myeloreductively conditioned host.  Mice that received T cell 
depleted BMC had high incidence of GVHD. This remained unaltered even when the 
mice received additional injections of IL-7. However the incidence of GVHD was 
reduced in mice receiving no vaccination. When mice received DP TC with or without 
IL-7; vaccination did not enhance the GVHD (Fig.7A). IL-7 application did not have a 
major impact on tumor take and survival of mice. But when mice were injected with 
DP TC along with BMC plus vaccination, tumor take was reduced and the survival 
rate was increased. Vaccinating the mice receiving BMC without DP, with or without 
IL-7 did not improve the survival time. However, the survival rate was improved 
significantly, almost doubled in mice reconstituted with DP TC and receiving 
vaccination (Fig.7B & C). The same observations accounted for mice receiving SP6 
vaccination. The survival time improved in mice reconstituted with DP TC plus BMC 
as compared to only T depleted BMC. Also the tumor take was lesser in these mice 
(Fig.7 D & E), suggesting that DP TC injection along with BMC creates a room for 
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Fig. 7 GVHD and GvT reactivity in myeloreductively conditioned mice reconstituted with Tdepl BMC plus                       
DP TC and vaccinated with tumor cells 
BALB/c mice conditioned and reconstituted as described in Fig.5 received a s.c. injection of a mixture of 
YC8.lacZ lysate (corresponding to 1x107 cells) and β-Gal (100µg / mouse) or of a mixture of Sp6 lysate 
(corresponding to 1x107 cells) and Sp6 IgM (150µg / mouse) in adjuvant at the day of tumor cell 
inoculation. Vaccination was repeated after 2wk (A) The percentage of mice succumbing with severe 
GVHD is shown. Significant differences as compared to mice reconstituted with Tdepl BMC are indicated 
by an asterisk. Significant differences between vaccinated and non-vaccinated mice are indicated by s 
(B and D) The number of mice developing tumors and (C and E) the mean survival time are presented 
(B-E) Significant differences between mice receiving only Tdepl BMC and the remaining groups are in-
dicated by an asterisk. Significant differences between non-vaccinated and vaccinated groups are 
indicated by s. 
 
 
Taken together, reconstitution of the myeloreductively conditioned host with Tdepl 
BMC plus DP TC obviously supports donor T cell tolerance induction, such that tumor 
vaccination is not accompanied by an aggravation of GVHD. These donor-derived, 
host-tolerant T cells can still mount an anti-tumor response, while the survival rate 
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Since transfer of DP TCs efficiently improved thymus reconstitution we wanted to 
further strengthen the protocol for allogeneic BMT with respect to thymus homing and 
maturation. Hence, it was important to study molecules that support thymus homing 
and maturation. CD44 has been proposed as a marker for T cell progenitors [44] and 
also facilitates thymus homing [178]. In addition, we reported previously that bone 
marrow cells from mice transgenic for the ratCD44v4-v7 variant isoforms had a clear 
advantage of repopulating the thymus over the wild type and in this case thymocytes 
also expanded earlier than the wild type mice. This effect could be blocked by an 
antibody against CD44v6 [169]. So we went on to explore the role of CD44 standard 
and variant isoforms v6 and v7 in thymocyte homing and maturation as stated below. 
 
3.7 Expression of adhesion molecules, interleukins and chemokines 
on hematopoietic progenitors and thymocytes 
 
Before exploring its role in thymus reconstitution, we looked for the expression of 
CD44 and its variants v6 and v7 in hematopoietic progenitors and thymocytes.  
CD44 expression in the bone marrow was the same in all mice strains, however in the 
thymus; Balb/c had highest expression of CD44 (80%), which decreased in the SVEV 
strain to around 40%. CD44v6 and v7 expression were almost similar in all strains in 
BMC and TC (Fig.8A). In the individual progenitors the expression of CD44 and 
variants did not vary much except that CD44v6 was highest in double negative (DN), 
lower in double positive (DP) and comparatively higher in single positive (SP) 
populations of thymocytes. The intensity of CD44 expression in DP TC was lower than 
in other populations (Fig.8B and C).  
 
Interaction of thymocytes with elements of the thymic microenvironment is very 
essential for the differentiation of thymocytes [59]. CD44 and CD49d interaction in 
peripheral T cells has been reported. This association resulted in the formation of a 
signaling complex between CD44, CD49d and the underlying signaling machinery 
allowing for each surface molecule (CD44 or CD49d) to avail from the associated 
signaling molecule of the other [154]. In this regard expression of additional adhesion 
molecules on thymocytes was checked.  CD49d, CD18, CD29 were expressed by a  
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majority of thymocytes between 60-80%. The expression of these molecules 
decreased to a great extent in DP TC. CD54 and CD62L were expressed by 50% of 
the thymocytes. Expression of CD103 was particularly high in DN population. All the 
markers also co-expressed CD44. Co-expression with CD44v6 was high for CD49d, 
CD18, CD29 and CD62L and low for CD103. Co-expression with CD44v6 did not vary 
with other adhesion molecules at different stages of maturation except CD62L co-
expression, which was less in DP (Fig.8D and E). 
 
Since IL-3 and IL-7 are major growth factors for TC [174] we looked for their 
expression at different stages of TC maturation. Expression of CCL25/CCR9 an 
important chemokine/chemokine receptor pair for TC maturation [54] were checked by 
semi-quantitative PCR. IL-3, IL-7 and CCL25 expression were stronger in CD4 SP. IL-
3R, IL-7R and CCR9 were highly expressed in DN. CCR9 expression was the highest 
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Fig. 8   Adhesion molecule, cytokine, chemokine and cytokine / chemokine receptor ex-
pression on subpopulations of BALB/c TC 
 (A) BALB/c, SVEV, SVEVv7-/- and SVEVv6/7-/- BMC and TC and (B) bone marrow- and 
thymus-derived progenitor subpopulations were stained with anti-panCD44, anti-CD44v6 and 
anti-CD44v7. The mean percentage ± SD of stained cells is shown. Differences between 
BALB/c and SVEV mice and between unseparated BMC / TC and subpopulations derived 
thereof are indicated by * (C) Examples on the intensity of CD44/CD44v6 expression on TC 
subpopulations. Single fluorescence overlays with the negative control are shown (D and E) 
Unseparated, DN, DP, CD4 SP and CD8 SP TC were double stained with (D) anti-CD44 or (E) 
anti-CD44v6 and antibodies against the indicated adhesion molecules or were stained (F) with 
anti-IL-3, -IL-7, -IL-3R or IL-7R. The percentage of single positive and double positive cells 
(mean values from 3-5 assays) is shown (G) CCL25 and CCR9 mRNA in TC subpopulations 




Taken together, BALB/c TC express CD44 and CD44v6 at a relatively high 
frequency. CD44v6 expression varies with the maturation stage with a transient 
decline in DP. CD44v7 expression is low throughout. Irrespective of the maturation 
stage, integrins are mostly co-expressed with CD44v6, which does not account to the  
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same degree for ICAM. The selectin CD62L, highly expressed in TC, is also co-
expressed with CD44v6, co-expression declines in DP. 
 
3.8 Retarded thymus repopulation in anti-CD44 treated 
syngeneically reconstituted mice 
 
In order to have a look whether CD44 standard or CD44v6/v7 isoforms are important 
for thymus homing and repopulation, lethally irradiated SVEV wild type mice 
with/without targeted deletion for CD44v6/7 or CD44v7 were reconstituted with BMC. 
Lethally irradiated and reconstituted Balb/c mice were used as an additional control. 
Alongwith TC we also checked bone marrow and spleen cells in parallel for better 
comparison. Balb/c and SVEV mice reconstituted with a good efficacy and reached 
normal numbers by week 4-6. CD44 v7-/- and v6/7-/-  mice reconstituted with a lower 
efficiency in BMC and SC. The effect of CD44v6/7-/- was more pronounced in TC 
(Fig.9A). To assess if anti-CD44 treatment interferes with reconstitution mice were 
treated with anti-panCD44 (recognizes standard and variant CD44 isoforms) twice 
per week.  The effect of inhibition was stronger in Balb/c than SVEV; probably due to 
higher CD44 expression in Balb/c. The effect became stronger in the bone marrow 
after 4-6wk of reconstitution (Fig.9B).  
 
To evaluate the role of variant CD44 isoforms v6 and v7 in homing, SVEV BMC were 
transferred into wild type SVEV or SVEVv7/-/- and SVEVv6/7-/-. Homing of SVEV 
BMC in the bone marrow of both knockout mice was reduced. In the spleen, slightly 
fewer cells were recovered in CD44v6/7-/- mice as compared to SVEV CD44v7-/- 
mice. In the thymus a weak effect was seen in the knockout mice receiving SVEV 
bone marrow, slightly lesser cells were recovered (Fig.9C). The other way round 
when bone marrow cells from knockout mice were reconstituted into SVEV mice, 
repopulation of BMC and spleen improved compared to the knockout mice. The 
recovery of TC in SVEV mice receiving BM from CD44v6/7-/- mice remained impaired 
(Fig.9D). This was an indication that CD44v6 on the thymic progenitors might be 
important in repopulating the thymus.           
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Fig. 9 The impact of CD44 on BMC reconstitution 
 (A) Lethally irradiated BALB/c, SVEV, SVEVv7-/- and SVEVv6/7-/- mice were reconstituted with 5x106 
autologous BMC (B) BALB/c and SVEV mice, reconstituted as described, received 100µg control IgG 
or anti-CD44, i.v. twice / week (C) SVEVv7-/- and SVEVv6/7-/- mice were reconstituted with 5x106 
SVEV BMC (D)  Lethally irradiated SVEV mice were reconstituted with 5x106 SVEVv7-/- or SVEVv6/7-/- 
BMC  (C and D) autologous reconstitution is included as control (A-D) Three mice / group were sacri-
ficed after 1-6wk. The mean number ± SD of BMC, TC and SC is shown. Significant differences 
between SVEV and SVEVv7-/- / SVEVv6/7-/- mice (A, C, D) and between control IgG- and anti-CD44-
treated mice are indicated by *. 
 
 
From the finding that anti-panCD44 exerts a stronger effect on BMC recovery at 6wk 
than 2wk after reconstitution we assume that anti-panCD44 interferes not only with 
BMC homing/settlement, but also with BMC expansion/maturation. Settlement of 
BMC is likely facilitated by stromal cell CD44v7, because BMC homing, but not 
expansion is reduced in CD44v6/7-/- / CD44v7-/- mice. Thymus homing too is affected 
by an anti-panCD44 blockade. CD44v6/7-/- mice are burdened, in addition, by 
reduced TC expansion, that is not compensated in the CD44v6/7comp (competent) 
host. This indicates a possible involvement of CD44v6 in TC expansion and/or 
maturation.  
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3.9 CD44 influences homing of hematopoietic progenitors into bone 
marrow and thymus 
 
The importance of CD44 in BMC homing was confirmed by labeling BMC cells with 
CFSE and injecting into mice. Spleen, TC and BMC cells were isolated and checked 
for CFSE labeled cells by FACS. When CD44v6/7-/- and CD44v7-/- were reconstituted 
with bone marrow cells from these knockout mice fewer bone marrow cells were 
recovered (Fig.10A).  However, when SVEV mice were reconstituted with bone 
marrow cells from CD44v6/7-/- mice, bone marrow reconstitution significantly 
improved. Reconstitution was still poor when SVEV BMC were injected into CD44v7-/-
(Fig.10B). The migratory activity of BMC was checked using all mice strains including 
the knockouts. When CFSE BMC were reconstituted along with anti-CD44 treatment 
into mice, the recovery of BMC in Balb/c and SVEV was reduced drastically. Less 
BMC were recovered in knockout mice and anti-CD44 treatment did not have much 
of an impact.  However, a higher number of cells were retained in the spleen of 
knockout mice after anti-CD44 treatment (Fig.10C).  
 
Bone marrow cells are a mixture of stem cells, lymphoid and myeloid progenitors and 
several subpopulations. To see which subpopulation might be affected by a blockade 
of CD44 or by a deficiency in CD44v6 or v7 isoforms, bone marrow cells from Balb/c 
were separated into lin+ (lineage positive), CLP1 (lin-ckit+IL-7Rα+)  and CLP2 (lin-c-
kitlo B220+)  as indicated in materials and methods, CFSE labeled and injected into 
Balb/c mice. In order to explore the role of CD44 in the homing of individual 
populations, mice were giving injections of anti-panCD44. Lin+ and CLP1 population 
homed with high efficiency into BM and the homing was inhibited with anti-CD44 
treatment. CLP2 homed with very less efficiency into BM (Fig.10D). To evaluate the 
role of isoforms in homing of these progenitors, the experiment was repeated with 
CFSE labeled SVEV BMC subpopulations injected into CD44v6/7-/-  mice and vice-
versa or injections  of wild type bone marrow cells into wild type and knockout bone 
marrow cells into knockout mice. The SVEV lin+ and CLP1 cells homed efficiently into 
SVEV host bone marrow. Homing of CD44v6/7-/- lin+ and CLP1 into CD44v6/7-/- mice 
was severely impaired. The homing capacity improved especially in CLP1 population 
when BMC of CD44v6/7-/- were injected into SVEV CD44v6/7comp  (competent) mice. 
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However they did not reach the level of lin+ and CLP1 from SVEV BMC. In addition, 
the homing still remained impaired when SVEV lin+ and CLP1 cells were injected into 
CD44v6/7-/- mice (Fig.10E).   




























Fig. 10 The impact of CD44 on TC  homing and reconstitution  
(A) 1x107 CFSE-labeled BALB/c, SVEV, SVEVv7-/-, SVEVv6/7-/- BMC were i.v. injected into lethally 
irradiated syngeneic mice; (B) SVEV BMC were injected into SVEVv7-/- mice or SVEVv6/7-/- BMC were 
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CFSE-labeled subpopulations (2x106) of BALB/c BMC were injected concomitantly with 150µg anti-
panCD44; (E) CFSE-labeled subpopulations (2x106) of SVEV BMC were injected into SVEVv6/7-/- mice 
and vice versa; (A and B) Mice were sacrificed after 24-72h or (C-E) 48h(A,B,C) The percentage of dye-
labeled SC and BMC or (D,E) the % recovery of input CFSE-labeled cells in spleen and bone marrow 
was evaluated by flow cytometry. Mean values ± SD of 3 mice / group are shown. Significant differences 
between SVEV and SVEVv7-/- / SVEVv6/7-/- or between control IgG and anti-panCD44 are indicated by *. 
 
 
Thus, CD44 considerably contributes to lin+ and CLP1 marrow homing. Furthermore, 
stromal cell CD44v7 is important to retain “homed” lin+ and CLP1. Retention of CLP2 
appears to be independent of stroma cell CD44v7. 
 
It is known that CD44 supports progenitor homing into thymus [179]. Since we also 
observed inhibition in homing of BMC into thymus using anti-CD44, we wanted to 
check which sub populations of BMC progenitors and TC subpopulations were 
susceptible to anti-CD44 treatment in homing into the thymus. We used Balb/c Lin+, 
CLP1, CLP2, DN, DP, SP populations to check for their homing capacity into thymus 
as well as the role of CD44 using anti-panCD44. Lin+ and CLP1 homed very poorly 
into thymus. CPL2 and DN1 homed with highest efficiency (2%) as compared to the 
rest, followed by DN2 and DN3.  We could show in addition, that homing of these sub 
populations was inhibited with anti-panCD44 (Fig.11A). 
 
We wanted to check next, if CD44 variant isoforms would be involved in the homing 
of these individual subpopulations into the thymus. The same experiment was further 
repeated using SVEV wild type and knockout for CD44v6/7. CLP2 homing was much 
higher as compared to unseparated BMC and TC in all mice. The lack of CD44v6 or 
v7 did not have any major impact on homing of these subpopulations into thymus. 
CD44v6 or v7 expression on the stroma of thymus doesn’t seem to have a major 
impact on homing of subpopulations into thymus, since transfer of SVEV bone 







                                                                    
                    


















Fig. 11  The impact of CD44 on TC homing 
(A) BALB/c-derived CFSE-labeled BMC (1x107) TC (1x107) and subpopulations (1x106 – 1x107) 
thereof were i.v. injected into lethally irradiated BALB/c, concomitantly with 150µg anti-panCD44; (B) 
SVEV- or SVEVv6/7-/-/-derived CFSE-labeled BMC (1x107) TC (1x107) and subpopulations (1x106 – 
1x107) thereof were i.v. injected into lethally irradiated SVEV or SVEVv6/7-/- mice. Mice were 
sacrificed after 48h. The % recovery of input CFSE-labeled cells in the thymus was evaluated by flow 
cytometry. Mean values ± SD of 3 mice / group are shown. Significant differences between SVEV and 
SVEVv7-/- / SVEVv6/7-/- or between control IgG and anti-panCD44 are indicated by *. 
 
 
These findings confirm preferential CLP2 homing into the thymus. TC subpopulations 
also home into the thymus, the homing capacity inversely correlating with maturation. 
A blockade of panCD44 affects progenitor homing. Since thymus repopulation is 
delayed in CD44v6/7-/- mice, we speculated that CD44v6 may contribute to early 
stages of T progenitor maturation. 
 
3.10 CD44v6 promotes proliferation of T progenitors in thymus 
 
In peripheral T cells it was shown that, anti-panCD44  when cross-linked along with 
sub threshold levels of anti-CD3 increases proliferation of T cells as compared to 
sub threshold levels of anti-CD3 alone [150]. Since we observed delay in 
repopulation of the thymus in CD44v6/7-/- mice it was worthwhile to check for 
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respect to pre-TCR, we repeated the same experiment in thymocytes as in 
peripheral T cells in two strains of mice Balb/c and SVEV including CD44v6/7-/- and 
v7-/- with SVEV background. Flat bottomed 96-well plates were coated with the 
specified antibodies o/n as described in materials and methods.  We saw the same 
effect in unseparated thymocytes that CD44 alone could not increase proliferation. 
Instead, after concomitant cross-linking with anti-CD3, the proliferation was much 
higher than anti-CD3 cross-linking alone. The effect was comparatively less in the 
case of CD44v6/7-/- mice (Fig.12A).  
 
In order to define the maturation stage of thymocytes at which CD44 has an effect, 
the experiment was repeated in different subpopulations of thymocytes. This time 
anti-CD44v6 cross-linking alone or with anti-CD3 concomitant cross-linking was 
also used since CD44v6/7-/- mice showed comparatively less proliferation in the 
previous experiment. Surprisingly, in the DN1 and DN2 subpopulations anti-CD44 
cross-linking alone also showed high proliferation that was not increased by 
concomitant anti-CD3 cross-linking in addition. The same effect was also seen with 
a CD44v6 specific antibody cross-linking. In DN3 and DN4 subpopulations 
however, anti-panCD44/v6 cross-linking did not exert an effect by themselves. Only 
when they were concomitantly cross-linked with anti-CD3, thymocytes showed high 
proliferation rates which were higher than after anti-CD3 cross-linking alone, but 
not as high as in DP or SP. In the DP population anti-panCD44 cross-linking 
showed high proliferation after concomitant cross-linking with anti-CD3, and anti-
CD44v6 could not mediate this effect as strong as pan CD44. In the SP populations 
proliferation was seen only when anti-panCD44 were concomitantly cross-linked 
with anti-CD3 and the effect was less pronounced with anti-CD44v6 cross-linking. 
SP cells weakly responded to CD44 or v6 cross-linking alone (Fig.12B). Since DP 
cells are the largest population of thymocytes (~85%) we suspect that the effect of 
CD44 alone on the proliferation of DN was hidden in total thymocytes.  
  
Since we observed high proliferative stimulus in thymocytes with respect to anti-
panCD44/v6 cross-linking, the next step was to gain insight into molecular 
mechanisms  involved  in  mediating  signals  through  panCD44/v6  or  CD3  plus  
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panCD44/v6 leading to proliferation. When pre-TCR complex signals are triggered 
it leads to recruitment and phosphorylation of several tyrosine kinases to the 
vicinity of the TCR receptor which leads to further activation of downstream 
signaling events such as the mitogen-activated protein kinase (MAPK) family and 
PI3K family  [74, 84]. So we looked for tyrosine phosphorylation events in reponse 
to anti-panCD44/v6 and or anti-CD3 cross-linking. Tyrosine phosphorylation 
became stronger when unseparated thymocytes, DP and SP were cross-linked 
with CD3 and panCD44/v6 in comparison to CD3 alone (Fig.12C). Next we looked 
for specific tyrosine kinases Lck and Zap-70 recruited at the pre-TCR complex. 
CD44/v6 cross-linking alone promoted phosphorylation of Lck and ZAP-70. But 
after this step panCD44/v6 could not mediate further events by themselves and 
required CD3 cross-linking. Since MAPK pathway is usually involved in mediating 
proliferation signals [180], thymocytes were activated with anti-CD3 and/or 
panCD44/v6 cross-linking and checked for ERK1/2 activation. Low level 
phosphorylation of ERK1/2 was mediated by CD3 cross-linking which was 
enhanced with panCD44/v6 and CD3 concomitant cross-linking in unseparated, DP 
and CD4SP TC (Fig.12D).  To further confirm the pathway involved in proliferation 
we used MEK1/2 inhibitor and performed the proliferation experiment as before. 
DMSO was used as control since inhibitors were diluted in it. MEK1/2 inhibitor 
strongly interfered with the proliferation of DN1 and DN2 in response to 
panCD44/v6 cross-linking (Fig.12E). MEK1/2 also inhibited the proliferation of DP 
and SP cross-linked with CD3 alone. The effect of inhibition of proliferation in DP 
and SP was more strongly pronounced after CD3 plus panCD44 concomitant 





                                                                    
                    




















































































































































































































































































































































                                                                    
                    




















Fig. 12 CD44 promotes thymocyte proliferation:  
(A) TC or (B) TC subpopulations were seeded in antibody-coated 96 well plates. Proliferation was 
evaluated by 3H thymidine incorporation after 48h. Mean values of triplicates ± SD are shown. 
Significant differences between (A) anti-CD3 (10µg/ml) and anti-CD44 (10µg/ml) plus anti-CD3 
(1µg/ml) or (B) between anti-CD3 (1µg/ml) and anti-panCD44/v6 (10µg/ml) or anti-panCD44/v6 
(10µg/ml) plus anti-CD3 (1µg/ml) are indicated by *(C and D) TC, DP and CD4 SP were stimulated for 
18min by seeding on antibody-coated plates. Cells were lysed and lysates were separated by SDS-
PAGE. After protein transfer, membranes were incubated with (C) anti-phosphotyrosine or (D) anti-lck 
/ anti-p-lck, anti-ZAP / anti-p-ZAP, anti-ERK1,2 / anti-p-ERK1,2. In (D) the ratio of p-lck: lck, p-ZAP70 : 
ZAP70, p-ERK1,2 : ERK1,2 are included (E and F) TC subpopulations were cultured for 48h on 
antibody-coated plates in the presence of 5µM MEK1,2 inhibitor. 3H-thymidine incorporation (mean 
values of triplicates ± SD) is presented as % of the DMSO control. 
 
Thus, CD44 ligation promotes lck and ZAP70 activation, at least partly, independent 
of TCR/CD3 complex ligation during TC maturation. At later maturation stages, CD44 



































































anti-CD3 (1) + anti-panCD44 (10)
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3.11 CD44 protects thymocytes from apoptosis during maturation 
Since CD44, particularly CD44v6 promoted proliferation of thymocytes, we were 
wondering whether it also plays a role in cell survival, since CD44v6/7-/- mice had a 
strong defect in reconstitution.  
 
Thymocytes from SVEV and CD44v6/7-/- mice were cross-linked with anti-CD3 and/or 
anti-panCD44/v6 over night and checked for apoptosis by AnnexinV staining on 
FACS. SVEV and not CD44v6/7-/-  mice were protected from apoptosis when cross-
linked with anti-panCD44/v6 (Fig.13A). This was the first indication that CD44 
protects thymocytes from apoptosis. We were inquisitive to know the signaling 
mechanism involved in panCD44/v6 mediated cell survival. Thymocytes were 
activated on antibody-coated plates. It was observed that increased apoptosis 
resistance mediated by panCD44/v6 was accompanied by Akt phosphorylation and 
Bcl-2 up-regulation. This effect was not seen in CD44v6/7-/-  mice indicating the 
involvement of CD44v6 in cell survival (Fig.13B). We then looked for the maturation 
stage of thymocytes at which this effect was mediated. So the same experiment was 
repeated using different subpopulations of thymocytes. The protection of apoptosis in 
SVEV mice through panCD44/v6 cross-linking was the strongest in DN; DP were 
partly protected, on the contrary CD4 and CD8 SP were driven into apoptosis 
(Fig.13C). CD3 cross-linking at high level concentration promoted apoptosis in DP 
and SP TC. Cross-linking CD3 (sub threshold level) plus CD44 promoted apoptosis 
in DP and SP TC (Fig.13D). It should be mentioned that CD44 mediated apoptotic 
effects in DP and SP thymocytes were more pronounced for panCD44 as compared 
to CD44v6.  To confirm the involvement of PI3K/Akt pathway the cross-linking 
experiment was repeated using PI3K inhibitor Ly49002.  DN1 cells which were 
protected from apoptosis by panCD44/v6 cross-linking remained respiratory active 
with medium dose of Ly49002. DP and SP that were driven into apoptosis by CD3 
and or panCD44/v6 cross-linking could survive in the presence of the inhibitor 
(Fig.13E). Thus expansion of DN population in response to panCD44/v6 cross-linking 
may partly also be due to increased cell survival. 
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Fig 13  The involvment of CD44v6 in apoptosis resistance  
(A) SVEV and SVEVv6/7-/- TC were seeded in antibody-coated 96-well plates. Annexin-FITC/PI 
staining was evaluated after 48h. Mean values ± SD of triplicates are shown. Significant differences to 
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BSA-coated plates are indicated by *(B) Unseparated TC were cultured for 24h in antibody-coated 
plates, lysed and, after separation by SDS-PAGE, blotted with anti-Akt / anti-pAkt, anti-Bcl2 and anti-
actin (C and D) TC subpopulations were seeded in antibody-coated 96-well plates. Annexin-FITC/PI 
staining was evaluated after 48h. Mean values ± SD of triplicates are shown. Significant differences to 
BSA-coated plates are indicated by *(E) TC subpopulations were cultured in antibody-coated 96-well 
plates in the presence of 5µM LY294002 (PI3-kinase inhibitor). After 48h, respiratory active cells were 
evaluated by MTT staining. Mean values of triplicates ± SD are presented as % of the DMSO control. 





































                                                                    
                    





Allogeneic bone marrow transplantation could be an ultimate curative therapy for 
patients with hematological malignancies as well as solid tumors like renal cell 
carcinoma [14].  Since the suggestion of non-myeloablative or myeloreductive 
conditioning as compared to the conventional myeloablative regimen has come into 
picture, this approach could be extended to a vast majority of patients. Elderly 
patients suffering from hematological malignancies and solid tumors can now be 
given bone marrow transplantation with non-myeloablative conditioning regimen [11, 
12]. However, even though tumor antigens exist and they have the ability to trigger 
an immune response it is known that patients suffering from tumors do not have 
sufficient immune responsiveness and this calls for a need of an external trigger like 
vaccination against specific tumor. In addition, vaccination protocol demands for a 
tolerance induction of donor T cells against the host [181]. This requires that donor T 
cells mature in the host thymus. 
 
In contrast to other blood cells that are generated in bone marrow, T lymphocytes 
develop in the thymus. The thymus contains no self renewing cells and requires bone 
marrow progenitors to home into it and mature to form functional T lymphocytes. 
Thymus involution starts at young age resulting in decreased thymic cellularity as 
well as emigration capacity [31, 32]. Now the question is how efficient is the thymus 
to promote thymocyte maturation and produce functional T cells that can recognize 
and kill the tumor after allogeneic bone marrow transplantation? Strategies to 
overcome this problem could decrease infectious complications, malignant relapse, 
resulting in improved survival rate of recipients receiving allogeneic BMT [182]. 
 
In our first experimental setup we observed that thymus repopulation is severely 
impaired in the lymphoma bearing mice.  In search for improving donor T cell 
tolerance and thymic reconstitution we discovered that even DP TC considered as 
late thymocytes are able to efficiently home into host thymus and mature, migrate to 
periphery and mediate GVT activity as functional T cells. Based on these findings we 
proceeded  to  further  improve  thymus  homing  with focus on CD44 that since many  
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years has been suspected to at least facilitate thymus homing, whereas its impact on 
thymocyte maturation has not yet been explored in detail. 
 
4.1 Lymphoma bearing mice show poor thymic reconstitution after 
allogeneic BMT 
 
Studies on mice receiving allogeneic bone marrow transplantation and tumor 
application (renal cell carcinoma) have revealed that there is poor repopulation of the 
thymus over weeks after reconstitution as compared to tumor free mice. In this case 
myeloreductive conditioning was applied and bone marrow cells were depleted of T 
cells. However, after weeks of reconstitution the number of donor derived T cells 
increased in the thymus consistently. Tolerance induction was achieved after 6 wk , 
probably due to maturation of donor derived cells in the host thymus developing into 
host tolerant T cells [173]. In our set of experiments with T and B lymphoma bearing 
mice given myeloreductive conditioning, donor cells in allogeneically reconstituted 
mice did not develop any tolerance towards the host. Thymus was very poorly 
populated even after weeks. Few thymic immigrants that were recovered were mostly 
host derived. It is known that strengthening the myeloreductive conditioning improves 
mixed donor host chimerism and results in better tolerance induction towards the 
host [173]. In our experiments the situation remained the same even when we used 
myeloreductive conditioning rather than non-myeloablative conditioning except that 
donor derived cell expansion could be improved slightly after strengthening the 
conditioning regimen.  
 
The question arose as to why immune reconstitution is strongly impaired in 
lymphoma bearing mice? One possible explanation could be a competition between 
T lymphoma and thymic progenitors to reside in the thymus. The reason behind this 
could be that lymphoma bearing mice might be bearing the same molecules for 
homing into thymus as T cell progenitors. One likely target is the homing receptor 
CD44. It has been shown that CD44 is expressed on lymphoma bearing cells. 
Functional relevance of this has been described as CD44 being involved in adhesion 
and migration of these cells on HA vasculature or ECM which is indeed important for  
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tumor dissemination [183]. Although standard form of CD44 is basically dominant in 
many tumors the variant isoform CD44v6 has also been proposed to be involved in 
migration and metastasis of tumor cells [102, 107].  A study by Krause et al, has 
shown the involvement of CD44 in homing of leukemic stem cells in a chronic 
myeloid leukemia model [184]. At the same time CD44 is also present on thymic 
progenitors and early thymocytes and has been shown to support thymocyte homing 
[44, 59].  Till date the factors responsible for interference of T or B lymphomas with T 
progenitor homing have not been identified to our knowledge. 
 
4.2 Cytokines promoted donor and host T cell expansion but failed 
to mediate tolerance induction in allogeneically reconstituted mice  
 
In our first trials to improve thymic reconstitution we used the cytokines IL-3 and IL-7. 
Studies with IL-7 application after bone marrow transplantation have shown 
enhanced thymic output as well has peripheral T cell counts. IL-7 also leads to strong 
expansion of newly formed naive T cells [60, 174, 185]. Our results showed increase 
in both host and donor derived hematopoietic progenitor cells. The anti- donor and 
anti-host activity remained high making it an unsuitable approach for patients. One 
possible reason could be an over load of allogeneic BMCs that are accompanied by 
a high number of T cells under going extrathymic maturation [173]. In the next step 
we strengthened the myeloreductive conditioning and observed an increase in donor 
derived cells homing into thymus. This can be due to increased donor T cell 
chimerism (more donor T cells in comparison to host) due to the conditioning regimen 
received. On the other hand this regimen was disadvantageous since mice 
developed high GVHD. A possible explanation could be that since host T cells 
decreased considerably in the stronger myeloreductive regimen this led to a sooner 
domination of donor T cells recognizing the host as foreign [175]. Hence we wanted 
to establish a protocol whereby thymus reconstitution can be achieved soon after 
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4.3 Injection of double positive thymocytes improves thymus 
reconstitution  
 
In our approach we decided to inject DP TC along with BMC depleted of T cells. Our 
hypothesis was that  DP TC might mature in the host thymus and hence become 
tolerant towards the host as well as kill tumor cells with high efficiency [4]. When we 
injected DP TC along with BMC depleted of T cells we observed efficient thymus 
repopulation. The DP TC selectively homed into thymus. A high percentage of cells 
recovered in the thymus was donor derived. In addition the number of T cells in the 
periphery also increased indicating that DP TC matured in the thymus and emigrated 
into the periphery. DP TC have the highest expression of CCR9. [54] We could 
confirmed this in our experiments as well. CCR9 is one of the chemokines essential 
for thymocyte homing as well as retention of thymocytes in the thymus [43, 45]. We 
speculate that DP TCs due to their high CCR9 expression can still receive signals 
form the thymic epithelial cells that express its chemokine partner CCL25 and thus 
preferentially home into the thymus. It would be of interest to investigate further 
molecules expressed on DP that facilitate their homing into thymus. 
 
4.4 DP injection induces tolerance induction and mediates GVT 
activity 
 
Reconstituting mice with DP TC resulted in decreased reactivity towards the host 
even after re-stimulation in vitro. However, there was sufficient reactivity against 
tumor without an increase in GVHD. Our approach also provided room for 
vaccination. Studies in animal models and humans indicated that donor T cells are 
able to kill tumor cells recognizing tumor-specific antigen or alloantigens expressed 
on normal and malignant cells [186]. We observed that 49 % (myeloreductively) and 
82% (myeloablatively) conditioned mice reconstituted with T cell depleted BMC plus 
DP TC rejected the SP6 tumor. Whereas in the situation without DP TC injection only 
21% (myeloreductive conditioning) and 46% (myeloablative conditioning) of 
vaccinated mice rejected the SP6 tumor. It has been a matter of great concern since 
long on how to separate GVHD from GVT due to their shared biology. Various  
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approaches have been proposed in this regard such as allograft T cell depletion, 
modulation of T cell response, donor lymphocyte infusion, use of T regs and so on. But 
till now none have shown optimal results that could be used as a standard method in 
allogeneic BMT [187]. It is also believed that increasing the stem cell dose would be 
a promising approach to improve immune reconstitution after transplantation, 
however there is always a limitation in getting high dose of stem cells and there also 
lies the risk of GVHD with remaining T cells in the allograft [188]. Hence DP TC could 
be exploited in this regard. At least this knowledge could be broadened to use thymic 
progenitors that would preferentially home into thymus and mature in the host, thus 
becoming host tolerant as well as mediating GVT effects.  
 
4.5 Injection of thymic precursors could be an ideal approach for 
better immune reconstitution and response in allogeneic BMT 
 
Recent evidence suggests many progenitors that preferentially home into the thymus. 
Most likely targets are the CLP2 (lin-c-kitlo B220+), early thymic progenitors (ETP-
DN1) and LSKs (Lin-Sca-1+c-kit+) [50-52]. These progenitors can be isolated and 
injected into the host during bone marrow transplantation. They would home into the 
thymus of the host and develop inside the host thymic microenvironment and be 
tolerant towards the host and active against the tumor. Another approach would be to 
induce T lineage potential by culturing hematopoietic stem cells on a widely accepted 
in vitro system using OP9-DLI cells proposed by Zuniga Pflucker [189]. Since they 
are T lineage committed progenitors, they would preferentially home into thymus and 
mature. An elegant study by Zakrzewski et al. has used hematopoietic stem cell 
precursors that were artificially committed towards the T cell lineage using OP9-DL1 
system and injected into mice along with bone marrow cells with T cell depletion. 
They were able to show that these precursors enhanced T cell reconstitution in 
thymus and peripheral reconstitution after hematopoietic stem cell transplantation 
and developed into any other functional T cells with high ratios of CD4 and CD8. 
Mice had enhanced resistance to infection and high graft vs tumor activity without 
induction of GVHD [182]. 
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The approach of administration of T cell precursors to enhance T cell reconstitution 
after allogeneic BMT can have a number of advantages. In the first instance its effect 
on engraftment would reduce the failure of graft rejection and relapse of the tumor. It 
would lead to better T cell functioning and thus reducing the risk to infections and 
morbidity. They would also create a room for vaccination much earlier after 
allogeneic BMT [182].  
 
 Taken together these set of data suggest DP TC and clinically more relevant early 
thymic progenitors can reconstitute the thymus efficiently after allogeneic BMT. They 
can also create a room for vaccination and thus a better anti-tumor response, by 
overcoming to some extent the prevailing problems of GVHD and graft rejection. 
Allogeneic bone marrow transplantation would provide a better therapy to patients of 
all ages suffering from tumors since it relies on establishment of a competent immune 
system. 
 
As mentioned before identifying thymic precursors that have high expression of 
molecules promoting their homing into thymus would add on to a better treatment in 
allogeneic BMT. In this regard, it is essential to identify molecules that support 
thymocyte homing and maturation. One of the homing molecules expressed in early 
thymocytes is CD44 [59]. So we explored the role of CD44 in homing, migration, 
proliferation and apoptosis which will be discussed further on. 
 
4.6 CD44s and variant isoforms expression on thymocytes and 
thymic progenitors 
 
PanCD44 (all isoforms including standard) expression was highest in Balb/c thymus 
as compared to SVEV, SVEV-CD44v6/7 knockout (KO) and SVEV-CD44v7 KO mice. 
Expression of CD44v6 and v7 remained the same in almost all strains. Expression of 
CD44 in individual thymocyte subsets revealed that its expression is high in almost all 
thymic subsets as well as CLP2 T cell progenitor. The intensity was lower in the DP 
population though. Expression of CD44v6 was highest in DN population and quite 
high in SP population, with decreased expression in DP TC. Data by Schwarzler et  
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al. in 2001 slightly contradicts to ours since they show that CD44 variant isoforms are 
not expressed after DN3 stage, but very low levels of CD44s remain, since we still 
see expression of v6 in DP stage as well as less amounts of v7.   
4.7 CD44 promotes homing of progenitors into bone marrow and 
thymus 
 
Interference of anti-CD44 with bone marrow cell homing has been studied widely.  
Avigador et al., have nicely shown how CD34+ progenitors home efficiently into bone 
marrow and spleen and that homing is inhibited with anti-CD44. Homing is mediated 
in association with stromal cell derived factor-1 and results in adhesion of cells in the 
niches of BM [190]. CD44 has also been shown to mediate adhesive interactions of 
stem cells with bone marrow vasculature [191]. Khaldoyanidi et al. have elegantly 
shown the requirement of CD44 in BM homing as well as proliferation of 
hematopoietic cells by establishing long term bone marrow cultures [192]. CD44v7 on 
bone marrow stromal cells contributes to progenitor settlement [167]. We could 
confirm the same in vivo using a syngeneic system. The decreased BMC settlement 
in v7-/- bone marrow led to increased settlement in spleen indicating that settlement in 
spleen doesn’t require CD44v7. In addition we were also able to show the individual 
involvement of CLP1 and lin+ progenitors into bone marrow that was hampered using 
anti-CD44. As far as homing is concerned we and others were not able to show a 
role for CD44 variant isofoms in homing [167, 192, 193].  
 
CD44 has also been described to be involved in thymus homing [179, 194]. We also 
observed that long term anti-CD44 treatment influences thymus homing. No 
involvement of variant isoforms was observed in thymus homing. We used thymic 
progenitors to check for their homing capacity. CLP2 cells home with high efficiency 
into thymus. Martin et al. have shown that CLP2 have a preference to home into 
thymus and develop into thymocytes and functional T cells [195]. We were able to 
show in addition that DN1 home with equal efficiency as CLP2. Anti-pan-CD44 
treatment almost abrogates homing of these two populations. A possible explanation 
could be that IM7 that does not bind to the hyaluron binding site of CD44 interferes 
with  CD44-integrin/ICAM/selectin  since  we  saw  a  high  co-expression  of  these  
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molecules with CD44. There was no evidence that CD44v6/v7 on thymus stroma 
influences homing. We only saw that recovery of TC in SVEV mice receiving BM from 
CD44v6/7 KO mice remained impaired. It is an indication for involvement of CD44v6 
in repopulating the thymus and intrathymic maturation. This led us to check for the 
role of CD44s and isoform v6 in thymocyte maturation. Studies by Schwarzler et al., 
(2001) revealed that CD44v are necessary for thymocyte development till they 
acquire DP state and hence they might play a role in establishing initial interaction 
between thymocytes and stroma but not critical for immigration and transmigration 
step of progenitors into thymus [196]. So far we did not succeed in finding the ligands 
for CD44s and variants in the thymus. Studies are underway. But it has to be 
considered that such selective ligands do not exist. However, it may be possible that 
CD44 is associated with CD49d or other adhesion molecules as shown for activated 
T cells [154]. Another likely target is CD62L, since studies on BM adhesion to stromal 
CD44 have shown the involvement of CD62E in mediating these interactions [197]. 
 
4.8 CD44 promotes expansion of early thymocytes  
 
Role of CD44 in promoting thymocyte expansion was supported by the finding that 
CD44 when cross-linked with sub-threshold level of CD3 provides a stronger 
proliferation stimulus as compared to CD3 alone, in the case of DP, CD4 and CD8 
SP.  So we propose that CD44 acts as a co-stimulatory molecule in these subsets of 
thymocytes just as described for peripheral T cells [150]. CD44 acting like CD28 as a 
co-stimulatory molecule for TCR mediated signaling is known already [150, 198]. 
 
Since proliferative signals of these thymocyte subsets were mediated through the 
pre-TCR we looked for the phosphorylation events of tyrosine kinases that get 
recruited towards the TCR upon activation [199]. We observed Lck and Zap-70 
phosphorylation mediated by panCD44/v6 plus CD3 cross- linking as well as 
panCD44/v6 cross-linking alone. This phenomenon differs from that of peripheral T 
cells where association of CD44 with Lck and in turn Lck co-localisation with the TCR 
makes a way for recruitment and phosphorylation of several other kinases necessary 
for T cell activation [150, 151].  
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The studies of signaling mechanisms involved in the proliferative effect revealed the 
involvement of the MAPK pathway. The MEK/ERK pathway is central for T cell 
receptor signaling with respect to differentiation, proliferation and survival since it 
integrates cytoplasmic signals to mediate these events [99]. ERK1/2 activation has 
been reported in thymocytes to be involved in positive and negative selection. 
Reports show that weak ERK phosphorylation promotes positive selection whereas 
stronger activation of ERK promotes negative selection [200]. Some reports suggest 
that sustained ERK phosphorylation leads to positive selection [201]. With our set of 
experiments we cannot speculate the possibilities in this direction. However, we 
could show that DP and SP thymocyte subsets needed CD3 plus panCD44 cross 
liking and not panCD44 cross linking alone for MAPK signaling. This shows that early 
activation events downstream of CD44 might be uncoupled from Ras pathway in DP 
and SP cells. Uncoupling Ras activation form early activation events at the TCR 
complex such as Lck and Zap-70 phosphorylation has been described in the case of 
anergic CD4 T cells and several candidate molecules may play a likely role in 
mediating uncoupling such as early growth response genes (Egr), ubiquitin ligases 
CBL-B, GRAIL and ITCH  [202].  CD44 is known to associate with Lck [151] and in 
turn Lck mediates activation of Ras/MAPK pathway in thymocytes [203]. This could 
be another possible explanation towards the results we observed. 
 
Assessment of DN thymocytes provided differing results. Anti-panCD44 cross-linking 
alone was enough to provide a proliferative stimulus in the DN1 and DN2 subsets 
and this was mediated via MAPK pathway. Anti-panCD44 binds to all isoforms of 
CD44 including the standard form. We cross-linked anti-CD44v6 in addition to anti-
panCD44 since we observed delayed repopulation in the CD44v6/7KO mice and also 
the proliferation in these mice was less as compared to wild type SVEV mice. We 
observed that proliferation of DN thymocytes was induced by the CD44v6 specific 
antibody. So we speculate that it is indeed CD44v6 that mediates these effects in 
early thymocytes. The proliferative response due to CD44 could be due to an 
interaction with an unknown ligand in the thymus. Our data are consistent with those 
of Graham et al., where they show CD44+ bone marrow chimeras as compared to 
CD44- have a higher capacity and preference to mature in thymus and develop into  
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functional T cells [194]. A role of CD44 in expansion of hematopoietic progenitor cells 
has been described before [192]. Transgenic mice bearing rat CD44v4-v7 have 
shown accelerated thymus repopulation [169]. In a CD44v6 over expressing 
thymoma line EL4 it was also shown that CD44v6 promotes proliferation via ERK1/2 
[157]. This finding might extend to DN TC. Our findings clearly depict the role of 
CD44v6 in DN thymocytes expansion and accessory function of CD44 with respect to 
DP, CD4 and CD8 SP thymocytes.   
 
4.9 CD44 contributes to apoptosis protection and cell survival in 
early thymocytes 
 
Since we saw high proliferation of thymocytes in response to CD44s/v6 we were 
keen to look whether CD44 also plays a role in survival pathways of thymocytes. 
Indeed, panCD44/v6 protected thymocytes from apoptosis when cross-linked alone. 
This effect was absent in CD44v6/7 KO mice, indicating an involvement of CD44v6 in 
apoptosis protection. Our results are well in line with those by Marhaba et al. in which 
EL4 thymoma line transfected with CD44v6 show apoptosis resistance mediated 
through CD44v6 cross linking [157].  The same was observed in separated TC 
subpopulations of DN and DP TC when they were cross-linked with anti-panCD44/v6 
alone.  The SP TC on the contrary were driven into apoptosis when cross-linked with 
CD44. 
 
Exploring the signaling pathway responsible for the increased cell survival in 
thymocytes revealed Akt phosphorylation and Bcl-2 upregulation after cross-linking 
with CD44v6 and this pathway was not activated in the CD44v6/7-/- KO mice. The 
involvement of PI3K/Akt pathway was confirmed using the PI3K inhibitor Ly49002. 
This could be a possible explanation for survival of DN TCs and expansion. 
Thymocyte development requires integration from several signaling events through 
pre-TCR, Notch, IL-7 for a programmed lineage commitment from DN and DP stage.  
The PI3K/Akt signaling acts at this point to  translate these signals towards a 
functional outcome such as survival, proliferation, differentiation and allelic exclusion 
at the β-selection check point, where only thymocytes with a fully functional pre-TCR 
(TCR β) are allowed to cross the DN3 stage to develop into DN4 and further DP TCs  
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[70]. Thymocytes with deletions of components of the PI3K/Akt pathway as in PI3K 
(p110γ subunit), PDK1 and Akt isoforms have an arrest at the DN3 stage and very 
low double positive thymocytes in consequence [72, 204]. In SP thymocytes CD44 
cross-linking alone promoted apoptosis of thymocytes. In addition, panCD44 cross-
linked with CD3 led to apoptosis induction which is consistent with data on T helper 
cell line [150]. 
 
Taken together our data suggest that delayed thymus reconstitution with CD44v6/7 
KO T progenitors is a consequence of early TC requirement of CD44v6 for expansion 
through MAPK pathway as well as survival of early thymocytes mediated via 
PI3K/Akt survival pathway and Bcl-2 upregulation that has an anti-apoptotic effect. In 
addition we were able to show for the first time that CD44 is involved in migration and 
homing of the T cell progenitors CLP2 and DN1. In later stages of thymocyte 
maturation the effect of CD44v6 vanishes and panCD44 acts as an accessory 
molecule similar to peripheral T cells in concert with CD3.  
 
4.10 Future perspectives 
 
Before exploring the therapeutic setup for improving thymus reconstitution in 
allogeneic bone marrow transplantation it would be worthwhile to investigate the 
mechanisms by which thymic progenitors home and mature in the thymus. Achieving 
host thymocyte reconstitution after bone marrow transplantation and retaining graft vs 
tumor activity without induction of GVHD would make this approach ideal for 
treatment of tumors and enhance survival rates of patients with hematological 
malignancies and solid tumors. 
 
Based on the observation that CD44s is required in progenitor T cell homing, defining 
the ligand on thymic stroma that provides a microenvironment for the differentiation of 
thymocytes would be important for clinical translation. Application of 
immunohistochemistry on thymic slices with recombinant soluble molecules of CD44s 
and variants generated in our lab would be a good tool to identify potential ligands 
such as a special form of hyaluronic acid, chemokines (CCR9, CXCL12) or 
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cytrokines (IL-7). Of equal importance will be a detailed analysis on the mechanisms 
whereby CD44v6 facilitates thymocyte maturation. Ongoing studies involving co-
immunoprecipitations of CD44v6 reveal the association of Lck (Src kinase). These 
studies have to be completed by checking for other potential partners interacting with 
CD44 such as CD49d, ICAM and CD62L. Should the hypothesis be correct that 
CD44 associates with CD49d or ICAM this would answer the question as to how 
CD44 mediates signaling in thymocytes by availing the associating molecules of one 
another such as Src kinases associated with CD44 and FAK associated with CD49d. 
In addition, it is also important to study the role of CD44 on the thymus stroma for 
thymocyte development and differentiation. The impact of CD44 on thymus homing, 
T cell maturation as well as on the thymic stroma can be therapeutically exploited to 
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A. In DN TC CD44v6 alone mediates signaling events of Lck phosphorylation followed by activation of 
MAPK pathway leading to cell proliferation. On the other hand CD44v6 cross-linking mediates 
activation of PI3K/Akt survival pathway and Bcl-2 upregulation, leading to cell survival. B. In DP and 
SP TC panCD44 can phosphotylate Lck and Zap-70 partly independent of CD3, but acts as a co-
stimulatory molecule in conert with CD3 to medate cell proliferation. CD44 alone leads to apoptosis in 
SP TC and concomitant crosslinking with CD3 can also lead to apoptosis in DP and SP TC. 
ABSTRACT 
                                                                    
                    
                                                                      105 
5.1 Abstract 
 
Active vaccination in the allogeneically reconstituted tumor bearing host essentially 
requires donor T cell tolerance. To create a basis for vaccination in the allogeneically 
reconstituted, lymphoma-bearing host, we elaborated a reconstitution protocol that 
supports thymus repopulation and tolerance induction. Myeloreductively conditioned, 
lymphoma-bearing mice were vaccinated after reconstitution with hematopoietic 
progenitor cells. In tumor-free mice, myeloreductive conditioning, together with NK 
cell depletion of the host and the transfer of T cell-depleted bone marrow cells, allows 
reconstitution without severe GVHD. However, in hematological malignancies, donor-
derived T progenitor cells hardly immigrated into the thymus. As a consequence, the 
frequency of severe GVHD was significantly increased, which prohibited active 
vaccination. Thymus repopulation became improved by strengthening the 
myeloreductive conditioning, by supporting thymocyte expansion via IL-7, and most 
strongly, by a small dose of donor-derived CD4+CD8+ thymocytes, which 
preferentially homed into the thymus. Active vaccination in combination with this 
reconstitution protocol did not strengthen GVHD, but significantly improved survival 
time and survival rate of lymphoma-bearing mice. 
 
The negative impact of hematological malignancies on thymus repopulation and 
central tolerance induction can, at least partly, be corrected by the application of a 
small number of donor-derived T progenitor cells. 
 
Based on these findings we proceeded to further improve thymus homing with focus 
on CD44 that since many years has been suspected to at least facilitate thymus 
homing, whereas its impact on thymocyte maturation has not yet been explored in 
detail. CD44 is known as a T progenitor marker. Antibody blocking studies and 
cells/mice with a targeted deletion of CD44v6/7 or CD44v7 revealed that CD44 has a 
major impact on progenitor cell homing into marrow and thymus. Marrow homing 
additionally is supported by stromal cell CD44v7, but thymus homing is CD44v6-
/CD44v7-independent. However, CD44v6 strengthens thymocyte expansion and 
apoptosis resistance. CD44v6-induced apoptosis resistance, most strongly in double 
negative (DN) cells, is accompanied by Akt activation. CD44v6-induced proliferation 
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of DN cells proceeds via the MAPK pathway. Instead, CD44-promoted proliferation of 
double-positive (DP) and single-positive (SP) thymocytes relies on CD44 supporting 
TCR/CD3 complex-initiated signal transduction. 
 
Thus, CD44 plays a major role not only in progenitor cell homing into bone marrow, 
but also in thymus homing. In addition, CD44v6 promotes survival and expansion of 
early thymocytes. Thus, strengthening CD44v6 expression on thymic progenitors 
could well contribute to accelerated regain of immunocompetence. 
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5.2  Zusammenfassung 
 
Allogene Knochenmarktransplantation nach nicht-myeloablativer Konditionierung 
wird in der Klinik in zunehmendem Maße als letzte Möglichkeit einer kurativen 
Therapie bei Tumorpatienten eingesetzt. Man weiß inzwischen, dass diese 
Therapieoption durch eine aktive Vakzinierung deutlich verbessert werden kann. 
Eine aktive Vakzinierung erfordert jedoch, dass die im Wirt gereiften Doner T-Zellen 
gegenüber dem Wirt tolerant sind. Hierzu müssen sie im Wirtsthymus reifen. Da bei 
älteren Menschen nur noch ein Thymusrudiment vorliegt, konnte dieses Problem in 
der klinik bisher nicht hinreichend gelöst werden. Daher habe ich im Rahmen meiner 
Dissertation versucht im Tiermodell Möglichkeiten aufzuzeigen, die die T-Zell-
rekonstitution nach allogener Knochenmarktransplantation unterstützen. 
 
Erste Untersuchungen zeigten auf, dass nach myeloreduktiver Konditionierung des 
allogenen Wirts eine verlässliche Rekonstitution mit T-Zell-depletierten und NK-Zell-
depletierten Knochenmarkzellen ohne schwerwiegende Graft versus Host (GvH) 
Erkrankung erzielt werden kann. Dies war jedoch im tumortragenden Tier nicht der 
Fall. Progenitor T-Zellen wanderten nicht in den Thymus und ein erheblicher 
Prozentsatz der Tiere entwickelte schwere GvH Störungen. Die Repopulation des 
Thymus konnte durch stringentere Myeloreduktion, Applikation von IL-7 und 
insbesondere durch die Applikation von unreifen CD4+ CD8+ T-Zellen verbessert 
werden. Die CD4+ CD8+  Vorläufer-T-Zellen wanderten präferentiell in den Thymus. 
Nach der Reifung tolerierten die tumortragenden Tiere eine Vakzinierung, welche die 
Überlebenszeit und Überlebensrate der Tiere signifikant verbesserte. 
 
Basierend auf diesen Ergebnissen und früheren Befunden, die eine Beteiligung von 
CD44 am Prozess der Immigration von Progenitor-T-zellen in den Thymus nahe-
legten, untersuchte ich, inwieweit CD44 am homing der Progenitor-T-Zellen und an 
deren Reifung beteiligt ist. Untersuchungen mit blockierenden Antikorper, sowie mit 
Mäusen mit einer targetierten Deletion von CD44v6/v7 oder CD44v7 belegten, dass 
die CD44 Standardform maßgeblich am Einwandern hämatopoetischer 
Progenitorzellen in das Knochenmark und den Thymus beteiligt ist. Das Einwandern 
in das Knochenmark wird darüber hinaus durch CD44v7 auf Stromazellen begünstigt. 
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Hingegen ist die Wanderung in den Thymus CD44v6/CD44v7 unabhängig. Allerdings 
verstärkt CD44v6 die Expansion und Apoptoseresistenz von insbesondere frühen, 
sogenannten doppel-negativen Thmyozyten. 
 
Die gesteigerte Apoptoseresistenz geht mit einer Aktivierung von Akt einher. Für die 
CD44v6-induzierte Proliferation doppel-negativer Thymozyten ist die Aktivierung der 
MAPK Signalkaskade verantwortlich. Dies gilt nicht für Thymozyten in einem 
späteren Reifestadium, in dem CD44 nur noch als akzessorisches Molekül die 
Aktivierung über den T-Zell-Rezeptor unterstützt. 
 
Diese Befunde belegen, dass CD44 nicht nur das Einwandern von Progenitor-T-
Zellen in den Thymus fördert, sondern darüber hinaus CD44v6 die frühen Stadien 
der Thymozytenreifung beschleunigt und somit eine wesentliche Rolle bei der 
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